Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
CA 03096311 2020-10-06
WO 2019/197965
PCT/IB2019/052867
1
PACKAGING OLIGONUCLEOTIDES
INTO VIRUS-LIKE PARTICLES
The present invention relates to processes for producing compositions
comprising (i)
a virus-like particle of an RNA bacteriophage, and (ii) aggregated
oligonucleotides,
wherein said aggregated oligonucleotides are packaged into said virus-like
particle. The
invention further provides processes for producing nucleotide compositions
comprising
aggregated oligonucleotides suitable for use in the aforementioned processes
before.
Moreover, the invention further provides nucleotide compositions comprising
aggregated
oligonucleotides. Furthermore, the invention further provides compositions
comprising (i) a
virus-like particle of an RNA bacteriophage, and (ii) aggregated
oligonucleotides, wherein
said aggregated oligonucleotides are packaged into said virus-like particle.
RELATED ART
Virus-like particles of RNA bacteriophages packaged with oligonucleotides, in
particular guanine (G)-rich oligonucleotides, are suggested as potent
stimulators of the
immune system. Such virus-like particles and oligonucleotides packaged therein
and
processes for their production have been described, for example, in
W02003/024481,
W02004/000351, W02004/084940, W02004/007538, W02007/068747 and
W02007/144150, the entire disclosures of which are incorporated by reference
herein.
Typically, the processes are based on the disassembly of a recombinant virus-
like particle
of RNA bacteriophage, the purification of the coat protein of said virus-like
particle and the
reassembly of said coat protein in the presence of the oligonucleotides
leading to the virus-
like particles packaged with the oligonucleotides. Efficient and scalable
processes for the
production of recombinant virus-like particles of RNA bacteriophages are
further disclosed,
for example, in W02005/117963, W02006/125821 and W02007/039552, which are
incorporated herein by reference in its entirety.
Methods of oligonucleotide synthesis have been available for over thirty years
with
the synthesis through phosphoramidite chemistry being the most commonly used
method
thereof (Beaucage et al., Curr Protoc Nucleic Acid Chem 3.3.1-3.3.20 (2000),
the entire
disclosure of which is incorporated herein by reference). There have been many
significant
improvements to phosphoramidite synthesis to reduce synthesis time and
generate higher
CA 03096311 2020-10-06
WO 2019/197965
PCT/IB2019/052867
2
yield of products. The synthesis of guanine (G)-rich oligonucleotides, in
particular the ones
with consecutive guanine residues, was always more challenging to achieve at
large
manufacturing scale, in particular at high purity and high yields, likely due
to the poor
accessibility of the 5'-hydroxyl group by the activated phosphoramidite in the
coupling
step. In particular, the support-bound protected G-rich oligomer can form
secondary
structures and have solubility issues after a certain length leading to
impurities and
synthesis failures most dominantly leading to oligonucleotide sequences with
lower number
of G residues or even higher G residues as desired. As a consequence, the
purity of the
commercially available guanine (G)-rich oligonucleotides has benefited
significantly from
said improvements made to phosphoramidite synthesis. Thus, while a purity of
60-80 % for
said guanine (G)-rich oligonucleotide had occasionally been accepted 10-20
years ago, a
purity as high as 93%, 95%, or even as high as 97 or 99% in analogy to the non-
guanine
(G)-rich oligonucleotides, is nowadays generally feasible. Moreover, if said
(G)-rich
oligonucleotides are part of pharmaceutical drugs, the use of such higher
purity (G)-rich
oligonucleotides is required and requested for regulatory approval.
G-rich oligonucleotides, in particular those with poly(G)s at the 5' and 3'
end and
further comprising unmethylated CG dinucleotide motifs and a central
palindrome, have the
tendency to self-assemble to higher order secondary and tertiary structures
via G-tetrad
formation of their poly(G) motifs (Kerkmann, M. et al., J. Biol. Chem., (2005)
280(9),
8086-93, Bochman, ML et al. Nat Rev Genet., (2012) 13(11): 770-780; the entire
disclosures of which are incorporated by reference herein). These G-
quadruplexes can form
via inter or intra molecular pathway and are very stable secondary structures.
As a result,
the size and shape and conformation of these quadruplexes can be quite
variable depending
on the reaction pathway.
W02007/144150 describes a process for producing compositions comprising
guanine
(G)-rich oligonucleotides packaged into virus-like particles of an RNA
bacteriophage,
wherein the self-assembly of the coat protein of the RNA bacteriophage is
performed in the
presence of oligonucleotide aggregates which have been obtained by a
disaggregation/aggregation process. The aggregation state of the
oligonucleotide is
characterized by the relative peak start time (PST) in size exclusion HPLC
using the capsid
of said RNA bacteriophage as standard and PST's of 50 to 110 %, preferably of
80 to 95 %,
has been found to be optimal. It is indicated that such PSTs correspond to
oligonucleotide
aggregates having an apparent molecular weight in the range of the apparent
molecular
CA 03096311 2020-10-06
WO 2019/197965
PCT/IB2019/052867
3
weight of the capsid of said RNA bacteriophage or slightly below. Despite its
improvements over the known processes for producing compositions comprising
guanine
(G)-rich oligonucleotides packaged into virus-like particles of RNA
bacteriophages, the
present inventors have identified substantial disadvantages of this prior art
process of
W02007/144150.
SUMMARY OF THE INVENTION
In particular, it has been found by the present inventors that aggregated
oligonucleotides prepared in accordance with the prior art process of
W02007/144150 and
being in accordance with the size distribution as defined in W02007/144150
showed
substantial inconsistencies and large variations with respect to the specific
size and
conformation of the formed aggregated oligonucleotides, as determined by
Dynamic Light
Scattering (DLS). In addition, said inconsistencies with respect to the
specific size and
conformation of the formed aggregated oligonucleotides led further to
substantial
inconsistencies in the virus-like particles packaged with said aggregated
oligonucleotides
causing not only the formation of the desired spherical packaged VLPs, but in
addition the
formation of malformed rod-like aggregates or higher order aggregates.
Moreover, said
resulting VLPs packaged with said highly polydispersed aggregated
oligonucleotides
showed not only a lower purity but further an increased instability.
Importantly, it has further been found that the prior art
disaggregation/aggregation
process of W02007/144150 is highly dependent on the initial purity of the
oligonucleotides
used for said disaggregation/aggregation steps. In particular, it has been
found that the
initial purity of the oligonucleotides used in the disaggregation/aggregation
process of
W02007/144150 has an impact on the aggregation of the oligonucleotides, i.e.
on the rate
of aggregation and, thus, the G-quadruplex formation, to form the defined
desired size and
conformation of the aggregated oligonucleotides. Typically, the higher the
purity of the
oligonucleotides used in the disaggregation/aggregation process of
W02007/144150, the
faster and more uncontrolled and chaotic the aggregation occurred resulting in
an increased
amount of typically very large aggregated oligonucleotides outside the desired
size
window. As a consequence, and since the resulting aggregated oligonucleotides
cannot be
properly packaged, the final oligonucleotides-packaged-VLPs had a decreased
purity
requiring intense and costly purification and a decreased stability as
evidenced by the
change in the SEC chromatogram overtime. Specifically, an increase in low
molecular
CA 03096311 2020-10-06
WO 2019/197965 PCT/IB2019/052867
4
weight peaks were observed overtime suggesting that some of the VLPs were not
stable and
released the originally packaged DNA and oligonucleotides, respectively,
Based on the findings by the inventors and, in particular, based on the large
dependency on the purity of the initially used oligonucleotides for the
disaggregation/aggregation process of W02007/144150, it appeared that the
processes of
W02007/144150, in particular the disaggregation/aggregation processes of
W02007/144150, have been developed and optimized for lower purity G-rich
oligonucleotides. As indicated, not only are high purity G-rich
oligonucleotides nowadays
ubiquitously available, but, furthermore, their use for pharmaceutical drugs
is a prerequisite
for regulatory approval. Moreover, a further substantial disadvantage of the
prior art
processes of W02007/144150, beside its inconsistencies and large variations
with respect
to the specific size and conformation of the formed aggregated
oligonucleotides depending
on the purity of the initially used oligonucleotides, is the herewith
associated very narrow
time window to achieve the preparation of the aggregated oligonucleotides in
the defined
size range due to the uncontrolled and chaotic aggregation.
As a consequence and due to these occurring inconsistencies and variations and
the
strong dependency on the purity of the initially used oligonucleotides, the
processes of
W02007/144150 are not suitable for manufacturing at scale, and in particular,
not suitable
for GMP manufacturing especially for clinical trial material where batch to
batch
consistency is critical.
Therefore, the present invention provides processes for producing a nucleotide
composition comprising aggregated oligonucleotides and for producing a
composition
comprising a virus-like particle of an RNA bacteriophage and aggregated
oligonucleotides
packaged in said virus-like particle, thus avoiding or reducing the
disadvantages of the prior
art processes.
Thus, in a first aspect, the present invention provides for a process for
producing a
nucleotide composition comprising aggregated oligonucleotides said process
comprising
the steps of:
(a) providing oligonucleotides, wherein said oligonucleotides comprise at
least one
poly G stretch;
(b) denaturing said oligonucleotides, wherein said denaturing comprises the
step of
(i) incubating an aqueous solution I comprising said oligonucleotides and a
chaotropic agent at a temperature I until the average diameter of said
CA 03096311 2020-10-06
WO 2019/197965
PCT/IB2019/052867
oligonucleotides is 1 nm or less, wherein said average diameter is
determined by Dynamic Light Scattering (DLS), and wherein said
temperature I is 75 C to 99 C, and wherein preferably said chaotropic agent
is urea;
5
(c) aggregating said oligonucleotides, wherein said aggregating comprises the
steps
of
(i) incubating an aqueous solution II comprising said oligonucleotides having
said average diameter of 1 nm or less obtained in step (b), a chaotropic
agent and a cation at a temperature II to form said aggregated
oligonucleotides, wherein said incubating is performed until the average
diameter of said formed aggregated oligonucleotides is 6-16 nm, wherein
said average diameter is determined by Dynamic Light Scattering (DLS),
and wherein said temperature II is 75 C to 99 C, and wherein preferably
said chaotropic agent is urea;
(ii) adjusting the temperature of said solution II to a temperature III,
wherein
said temperature III is below 40 C, preferably below 30 C;
wherein said steps are preferably performed in the given order.
Advantageously, the inventive processes allow the control of the size of the
formed
aggregated oligonucleotides, and, hereby, the conformation of aggregated
oligonucleotides,
and as a consequence thereof, the consistent formation of highly pure, stable
and well-formed,
namely typically exclusively spherical VLPs packaged with oligonucleotides.
Thus, the inventive processes allow control of the size of the aggregated
oligonucleotides by their diameter of between 6-16 nm, preferably 7-14 nm,
further
preferably 8-14 nm, again further preferably 9-14 nm, again further preferably
10-14 nm,
again further preferably 11-13 nm, thus 11, 12 or 13 nm, and most preferably
12 nm,
wherein said diameter is determined by Dynamic Light Scattering (DLS).
Importantly, the inventive processes allow not only control of the size and
thus, the
conformation of the formed aggregated oligonucleotides, but in addition to do
so regardless
of the purity of the oligonucleotides used for the denaturing step.
Furthermore, the
inventive processes further enable and provides a wider operating window in
which to
perform the aggregation step as it allows control of the aggregation. Such
control and
additional time and wider operating window, respectively, as well as the
higher preciseness
in the process controls, make the inventive processes highly beneficial for
the costly
CA 03096311 2020-10-06
WO 2019/197965 PCT/IB2019/052867
6
production in GMP quality, in particular large-scale GMP quality. Moreover,
the yield of
the final obtained oligonucleotide-packaged¨VLPs is additionally much higher
and more
pure, in particular, without the need of further costly purification steps.
As indicated, the prior art processes of W02007/144150 led to the formation of
aggregated oligonucleotides that showed substantial inconsistencies and large
variations
with respect to the specific size and conformation of the formed aggregated
oligonucleotides, as determined by Dynamic Light Scattering (DLS), in contrast
to the
aggregated oligonucleotides formed by the present inventive processes. It has
to be noted,
however, that the aggregated oligonucleotides formed by the present inventive
processes all
met the specification criteria of the relative peak start time (PST), in size
exclusion HPLC
using the capsid of said RNA bacteriophage as standard, as defined in
W02007/144150,
even though the corresponding optimal range is slightly shifted. Thus, the
preferred
aggregated oligonucleotides formed by the present inventive processes do
possess a PST as
determined accordingly of 90-105%, preferably of 92%-102%.
A further advantage of the inventive processes is the avoidance of salts and,
in
particular, the use of a chaotropic agent, preferably urea, for the denaturing
step as
compared to the prior art process of W02007/144150. As a consequence, the
resulting
solutions of the inventive processes containing the denatured, typically
monomeric,
oligonucleotides are stable without the threat of re-aggregation and thus,
could be stored for
further use. As such, these solutions may be heated or cooled multiple times
without
forming aggregates, and advantageously, could be frozen for future use. The
latter has not
been possible for the prior art processes most likely as indicated due to the
presence of salt
produced during neutralization step required to stop the denaturing step prior
to
oligonucleotide degradation. Thus, said prepared prior art solutions had to be
subsequently
used without the possibility of storage.
For the present invention, the aggregation state of the oligonucleotide is
characterized
by Dynamic Light Scattering (DLS) which measures the time-dependent
fluctuations in the
scattered light. The hydrodynamic radii and diameters of the aggregated
oligonucleotides are
then calculated by relating the rate of diffusion of the aggregate through the
solvent.
Aggregated oligonucleotides comprising an average hydrodynamic diameter of 6-
16 nm,
preferably 7-14 nm, further preferably 8-14 nm, again further preferably 9-14
nm, again
further preferably 10-14 nm, again further preferably 11-13 nm, thus, 11, 12
or 13 nm, and
most preferably 12 nm, has been found to be optimal.
CA 03096311 2020-10-06
WO 2019/197965 PCT/IB2019/052867
7
Thus, in a further aspect, the present invention provides for a process for
producing a
composition comprising (i) a virus-like particle, wherein said virus-like
particle is a virus-
like particle of an RNA bacteriophage, and (ii) aggregated oligonucleotides,
wherein said
aggregated oligonucleotides are packaged into said virus-like particle, said
process
comprising the steps of:
(a) generating a mixture, wherein said mixture comprises:
(i) a coat protein of said RNA bacteriophage;
(ii) an agent capable of preventing the self-assembly of said coat protein;
and
(iii) aggregated oligonucleotides, wherein said aggregated oligonucleotides
comprise oligonucleotides comprising at least one poly G stretch, and wherein
said aggregated oligonucleotides have an average diameter of 6-16 nm, wherein
said average diameter is determined by Dynamic Light Scattering (DLS);
(b) removing said agent from said mixture; and
(c) allowing said coat protein to self-assemble into a virus-like particle and
to package
said aggregated oligonucleotides.
In an again further aspect, the present invention provides for a process for
producing
a composition comprising (i) a virus-like particle, wherein said virus-like
particle is a virus-
like particle of an RNA bacteriophage, and (ii) aggregated oligonucleotides,
wherein said
aggregated oligonucleotides are packaged into said virus-like particle, said
process
comprising the steps of:
(a) generating a mixture, wherein said mixture comprises:
(i) a coat protein of said RNA bacteriophage;
(ii) an agent capable of preventing the self-assembly of said coat protein;
and
(iii) aggregated oligonucleotides, wherein said aggregated oligonucleotides
comprise oligonucleotides comprising at least one poly G stretch, and wherein
said aggregated oligonucleotides are obtainable by the process according to
the
first aspect of the present invention, and wherein said aggregated
oligonucleotides
have an average diameter of 6-16 nm, wherein said average diameter is
determined by Dynamic Light Scattering (DLS);
(b) removing said agent from said mixture; and
(c) allowing said coat protein to self-assemble into a virus-like particle and
to package
said aggregated oligonucleotides.
In an again further aspect, the present invention provides for a process for
producing
CA 03096311 2020-10-06
WO 2019/197965 PCT/IB2019/052867
8
a composition comprising (i) a virus-like particle, wherein said virus-like
particle is a virus-
like particle of an RNA bacteriophage, and (ii) aggregated oligonucleotides,
wherein said
aggregated oligonucleotides are packaged into said virus-like particle, said
process
comprising the steps of:
(a) generating a mixture, wherein said mixture comprises:
(i) a coat protein of said RNA bacteriophage;
(ii) an agent capable of preventing the self-assembly of said coat protein;
and
(iii) the nucleotide composition comprising said aggregated oligonucleotides,
and
wherein said nucleotide composition is obtainable by the process for producing
a
nucleotide composition comprising aggregated oligonucleotides in accordance
with the present invention, and wherein said aggregated oligonucleotides
comprise oligonucleotides comprising at least one poly G stretch, and wherein
said aggregated oligonucleotides have an average diameter of 6-16 nm, wherein
said average diameter is determined by Dynamic Light Scattering (DLS);
(b) removing said agent from said mixture; and
(c) allowing said coat protein to self-assemble into a virus-like particle and
to package
said aggregated oligonucleotides.
During said processes said virus-like particle is formed by self-assembly of
coat protein
of said RNA bacteriophage in the presence of said aggregated oligonucleotides.
In an again further aspect, the present invention provides for a nucleotide
composition
comprising aggregated oligonucleotides, wherein said nucleotide composition is
obtainable by
the process for producing a nucleotide composition comprising aggregated
oligonucleotides in
accordance with the present invention, wherein preferably said aggregated
oligonucleotides
have an average diameter of 6-16nm, preferably 7-14 nm, wherein said average
diameter is
determined by Dynamic Light Scattering (DLS).
In an again further aspect, the present invention provides for a nucleotide
composition
comprising aggregated oligonucleotides, wherein said aggregated
oligonucleotides have an
average diameter of 7-14 nm, wherein said average diameter is determined by
Dynamic Light
Scattering (DLS).
In an again further aspect, the present invention provides for a composition
comprising
(i) a virus-like particle of an RNA bacteriophage, and (ii) aggregated
oligonucleotides,
wherein said aggregated oligonucleotides are packaged into said virus-like
particle, wherein
CA 03096311 2020-10-06
WO 2019/197965 PCT/IB2019/052867
9
said composition is obtainable by a process for producing a composition
comprising (i) a
virus-like particle, wherein said virus-like particle is a virus-like particle
of an RNA
bacteriophage, and (ii) aggregated oligonucleotides in accordance with the
present invention.
In an again further aspect, the present invention provides for a composition
comprising
(i) a virus-like particle of an RNA bacteriophage, and (ii) aggregated
oligonucleotides,
wherein said aggregated oligonucleotides are packaged into said virus-like
particle, wherein
said aggregated oligonucleotides have an average diameter of 6-16, preferably
of 7-14 nm,
wherein said average diameter is determined by Dynamic Light Scattering (DLS).
Further aspects and embodiments of the present invention will be become
apparent as
this description continues.
DESCRIPTION OF FIGURES
FIG. IA: Dynamic Light Scattering (DLS) of denatured oligonucleotide G10 and
aggregated oligonucleotides G10 as obtained by the inventive process. DLS was
performed
as described in Example 3. FIG. lA shows denatured high purity G10
oligonucleotide with an
average particle diameter of 0.90 nm indicating that the G10 oligonucleotide
secondary
structures have been disrupted, denaturing is complete, and monomers have been
achieved.
Multiple scans were performed as shown by the overlapping curves. The average
diameter
(Dhyd) and percent of primary peak (mean) of these scans are reported within
data box inset in
the graph.
FIG. IB: Dynamic Light Scattering (DLS) of denatured oligonucleotide G10 and
aggregated oligonucleotides G10 as obtained by the inventive process. DLS was
performed
as described in Example 3. FIG. 1B shows the subsequently aggregated G10
oligonucleotides
obtained with proper aggregation and a diameter of 12 nm. Multiple scans were
performed as
shown by the overlapping curves. The average diameter (Dhyd) and percent of
primary peak
(mean) of these scans are reported within data box inset in the graph.
FIG. 2A: DLS of denatured oligonucleotides G10. DLS was performed as described
in
Example 3. Low purity oligonucleotide G10 of SEQ ID NO:1 (about 79% as
determined by
reverse phase HPLC and anion Exchange HPLC) was used for the disaggregation
(denaturation) as described in the prior art (W02007/144150). DLS shows
particles with an
average diameter of 2.2 nm indicating that not all oligonucleotide G10
secondary structure
has been disrupted and denatured to monomer. Multiple scans were performed as
shown by
CA 03096311 2020-10-06
WO 2019/197965
PCT/IB2019/052867
the overlapping curves. The average diameter (Dhyd) and percent of primary
peak (mean) of
these scans are reported within data box inset in the graph.
FIG. 2B: DLS of denatured oligonucleotides G10. DLS was performed as described
in
Example 3. High purity oligonucleotide G10 of SEQ ID NO:1 (about 94% as
determined by
5 reverse phase HPLC and anion Exchange HPLC) was used for the disaggregation
(denaturation) as described in the prior art (W02007/144150). DLS shows
particles with an
average diameter of 2.8 nm indicating that not all oligonucleotide G10
secondary structure
has been disrupted and denatured to monomer. Multiple scans were performed as
shown by
the overlapping curves. The average diameter (Dhyd) and percent of primary
peak (mean) of
10 these scans are reported within data box inset in the graph.
FIG. 2C: DLS of denatured oligonucleotides G10. DLS was performed as described
in
Example 3. High purity oligonucleotide G10 of SEQ ID NO:1 (about 94% as
determined by
reverse phase HPLC and anion Exchange HPLC) was used for the denaturation of
the
inventive process. DLS shows particles with an average diameter of 0.9 nm
indicating that
oligonucleotide G10 has been completely or substantially completely denatured
to monomer.
Multiple scans were performed as shown by the overlapping curves. The average
diameter
(Dhyd) and percent of primary peak (mean) of these scans are reported within
data box inset in
the graph.
FIG. 3A: DLS of aggregated oligonucleotides G10. DLS was performed as
described in
Example 3. Denatured oligonucleotides as obtained from Example 5 (FIG. 2A-2C)
were used.
Aggregation as described in the prior art (W02007/144150) of low purity G10
denatured by
prior art process. Low purity oligonucleotide G10 of SEQ ID NO:1 corresponds
to about 79%
purity as determined by reverse phase HPLC and anion Exchange HPLC. DLS shows
aggregated oligonucleotides which are not only on the high side of the desired
particle range
(15 nm), but additionally, 10% of the material is significantly larger (30-50
nm). Multiple
scans were performed as shown by the overlapping curves. The average diameter
(Dhyd) and
percent of primary peak (mean) of these scans are reported within data box
inset in the graph.
FIG. 3B: DLS of aggregated oligonucleotides G10. DLS was performed as
described in
Example 3. Denatured oligonucleotides as obtained from Example 5 (FIG. 2A-2C)
were used.
Aggregation as described in the prior art (W02007/144150) of high purity G10
denatured by
prior art process. High purity oligonucleotide G10 of SEQ ID NO: XX
corresponds to about
94% purity as determined by reverse phase HPLC and anion Exchange HPLC. DLS
shows
aggregated oligonucleotides with an average diameter being completely (100%)
outside the
CA 03096311 2020-10-06
WO 2019/197965
PCT/IB2019/052867
11
diameter range of 6-16 nm (the desired range) as illustrated by the shaded
box. Multiple scans
were performed as shown by the overlapping curves. The average diameter (Dhyd)
and percent
of primary peak (mean) of these scans are reported within data box inset in
the graph.
FIG. 3C: DLS of aggregated oligonucleotides G10. DLS was performed as
described in
Example 3. Denatured oligonucleotides as obtained from Example 5 (FIG. 2A-2C)
were used.
Aggregation of high purity G10 in accordance with the present inventive
process. High purity
oligonucleotide G10 of SEQ ID NO:1 corresponds to about 94% purity as
determined by
reverse phase HPLC and anion Exchange HPLC. DLS shows aggregated
oligonucleotides
with an average diameter of said aggregated oligonucleotides being completely
(100%) within
the diameter range of 6-16 nm (the desired range) as illustrated by the shaded
box. Multiple
scans were performed as shown by the overlapping curves. The average diameter
(Dhyd) and
percent of primary peak (mean) of these scans are reported within data box
inset in the graph.
FIG. 4A: Characterization of purified QI3 coat protein by analytical size
exclusion
chromatography. Sample of purified QI3 VLP. The observed peak (ratio A260/A280
= 2) is
dominated by the RNA core of the VLP, because the absorption coefficient of
RNA at
260 nm is approx. 100 fold higher than the absorption coefficient of the coat
protein.
FIG. 4B: Characterization of purified QI3 coat protein by analytical size
exclusion
chromatography. Sample of the supernatant of the disassembly reaction.
Released coat protein
is indicated by the presence of the protein-like peak at approx. 12 min.
Furthermore several
species of non-precipitated RNA molecules are present in the range 6.8 to 11
min.
FIG. 4C: Characterization of purified QI3 coat protein by analytical size
exclusion
chromatography. Sample of purified QI3 coat protein. Analysis was performed in
PBS on
column TS K G5000PWx1 (To soh B io science) .
FIG. 5A: DLS and Electron Micrographs (EM) pictures of virus-like particle
(VLP) of
RNA bacteriophage QI3 packaged with aggregated oligonucleotides G10 obtained
by the
disaggregation-aggregation method of prior art and by the denaturation and
aggregation of the
present invention. DLS was performed as described in Example 3 and EM was
taken as
described in Example 8. DLS of QI3VLPs packaged with aggregated
oligonucleotides G10
obtained by the disaggregation-aggregation method of the prior art. Multiple
scans were
performed as shown by the overlapping curves. The average diameter (Dhyd) and
percent of
primary peak (mean) of these scans are reported within data box inset in the
graph.
FIG. 5B: DLS and Electron Micrographs (EM) pictures of virus-like particle
(VLP) of
RNA bacteriophage QI3 packaged with aggregated oligonucleotides G10 obtained
by the
CA 03096311 2020-10-06
WO 2019/197965
PCT/IB2019/052867
12
disaggregation-aggregation method of prior art and by the denaturation and
aggregation of the
present invention. DLS was performed as described in Example 3 and EM was
taken as
described in Example 8. EM of QI3VLPs packaged with aggregated
oligonucleotides G10
obtained by the disaggregation-aggregation method of the prior art. Arrows
included to
identify the rod like structures.
FIG. 5C: DLS and Electron Micrographs (EM) pictures of virus-like particle
(VLP) of
RNA bacteriophage QI3 packaged with aggregated oligonucleotides G10 obtained
by the
disaggregation-aggregation method of prior art and by the denaturation and
aggregation of the
present invention. DLS was performed as described in Example 3 and EM was
taken as
described in Example 8. DLS of QI3VLPs packaged with aggregated
oligonucleotides G10
obtained by the inventive process. Multiple scans were performed as shown by
the
overlapping curves. The average diameter (Dhyd) and percent of primary peak
(mean) of these
scans are reported within data box inset in the graph.
FIG. 5D: DLS and Electron Micrographs (EM) pictures of virus-like particle
(VLP) of
RNA bacteriophage QI3 packaged with aggregated oligonucleotides G10 obtained
by the
disaggregation-aggregation method of prior art and by the denaturation and
aggregation of the
present invention. DLS was performed as described in Example 3 and EM was
taken as
described in Example 8. EM of QI3VLPs packaged with aggregated
oligonucleotides G10
obtained by the inventive process.
DETAILED DESCRIPTION OF THE INVENTION
Unless defined otherwise, all technical and scientific terms used herein have
the same
meanings as commonly understood by one of ordinary skill in the art to which
this invention
belongs.
Average diameter: The term "average diameter" as determined by Dynamic Light
Scattering (DLS), as used herein, refers to a diameter as measured typically
and preferably by
DLS in the manner as described in Example 3, and which given average diameter
value of
measured particles, refers to particles having said diameter as the mean in a
normal
distribution (Gaussian distribution). Thus, the term "average diameter" as
determined by
Dynamic Light Scattering (DLS), as used herein, and as typically and
preferably applied to
the oligonucleotides, aggregated oligonucleotides and VLPs packaged with
aggregated
oligonucleotides in accordance with the present invention, typically and
preferably refers to a
diameter as measured by DLS, typically and preferably in the manner as
described in
CA 03096311 2020-10-06
WO 2019/197965
PCT/IB2019/052867
13
Example 3, and which given average diameter value of measured particles,
refers to particles,
wherein at least 90%, preferably at least 95%, of said particles have a
diameter of said given
value or a diameter of 10% of said given value. By way of clarification, for
example, an
average diameter value of 12 nm of the inventive aggregated oligonucleotides
refers to said
inventive aggregated oligonucleotides, wherein at least 90%, preferably at
least 95%, of said
inventive aggregated oligonucleotides have a diameter of 10.8 nm to 13.2 nm.
Further, the
term "average diameter" as determined by Dynamic Light Scattering (DLS), as
used herein,
and as typically and preferably applied to the oligonucleotides, aggregated
oligonucleotides
and VLPs packaged with aggregated oligonucleotides in accordance with the
present
invention, typically and preferably refers to a diameter as measured by DLS,
typically and
preferably in the manner as described in Example 3, and which given average
diameter value
of measured particles, refers to particles, wherein at least 65%, preferably
at least 70%, of
said particles have a diameter of said given value or a diameter of 5% of
said given value.
By way of clarification, for example, an average diameter value of 12 nm of
the inventive
aggregated oligonucleotides refers to said inventive aggregated
oligonucleotides, wherein at
least 65%, preferably at least 70%, of said inventive aggregated
oligonucleotides have a
diameter of 11.4 nm to 12.6 nm.
All ranges of values, in particular all ranges of average diameters or
diameters disclosed
herein, should refer to all values falling within said range including the
values defining the
range. By way of clarification, for example, a diameter value of 12 nm to 13
nm should refer
to a diameter of 12nm or 13 nm or all diameters falling within 12 nm and 13
nm.
Chaotropic agent: The term "chaotropic agent" as used herein refers to a
molecule or
substance that disrupts the ordered structure of a protein, oligonucleotide,
or other
macromolecule. This decrease in stability is typically caused by the
disruption of the
hydrogen bonding network. Examples include urea, phenol, isopropyl alcohol
(IPA), ethanol
and guanidinium chloride amongst others.
Oligonucleotide: The term oligonucleotide as used herein refers to a single
stranded
deoxyribonucleotide. A preferred oligonucleotide comprises at least one poly G
stretch as
defined below. More preferred oligonucleotides comprise 2, 3, 4, 5 or 6 of
said poly G
stretches. Very preferred oligonucleotides comprise exactly two poly G
stretches, wherein
preferably one of said two poly G stretches is located at the 5' end or at the
3' end of said
oligonucleotide. Even more preferred oligonucleotides comprise exactly two
poly G stretches,
wherein one of said two poly G stretches is located at the 5' end of said
oligonucleotide and
CA 03096311 2020-10-06
WO 2019/197965
PCT/IB2019/052867
14
one of said two poly G stretches is located at the 3' end of said
oligonucleotide. Typically and
preferably, an oligonucleotide as used herein consists of 6 to 1000,
preferably of 10 to 1000,
more preferably of 10 to 200, still more preferably of 10 to 100, still more
preferably of 20 to
40, and most preferably of 30 nucleotides. Further preferred oligonucleotides
consist of 15,
16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34,
35, 36, 37, 38, 39, or
40 nucleotides. Still more preferred oligonucleotides consists of 24 to 32
nucleotides, more
preferably of about 30 nucleotides.
The term oligonucleotide also refers to molecules comprising at least one
modified
nucleotide, wherein preferably said modified nucleotide is selected from (a) a
nucleotide
analogue or (b) a nucleotide comprising a backbone modification. In one
embodiment the
oligonucleotide comprises at least one modified nucleotide selected from the
group consisting
of (a) peptide nucleic acid, (b) inosin, (c) tritylated bases, (d)
phosphorothioates, (e)
alkylpho sphorothio ate s, (f) 5 -nitroindole de soxyribofurano s yl, (g) 5 -
methylde soxyc yto sine,
and (h) 5,6-dihydro-5,6-dihydroxydesoxythymidine. In a further embodiment the
oligonucleotide comprises or alternatively consists of phosphorothioated
nucleotides.
Phosphorothioated nucleotides are protected against degradation in a cell or
an organism and
are therefore preferred nucleotide modifications. Further preferred are
chemically,
enzymatically or metabolically modified forms of polynucleotides as typically
found in
nature. However, preferred oligonucleotides exclusively consists of unmodified
nucleotides,
i.e. of adenosine, tymidine, guanosine, and/or cytidine. Still further
preferred oligonucleotides
exclusively consists of phosphodiester bound nucleotides.
Very preferred oligonucleotides are unmethylated CpG containing
oligonucleotides
comprising at least one, preferably one, two, three or four CpG motifs. Still
more preferred
oligonucleotides comprise a palindromic sequence, wherein preferably said
palindromic
sequence comprises least one, preferably one, two, three or four CpG motifs.
Still more
preferred oligonucleotides comprise a palindromic sequence, wherein preferably
said
palindromic sequence comprises, or preferably consists of the sequence
GACGATCGTC
(SEQ ID NO:2). Still more preferred oligonucleotides comprise a palindromic
sequence,
wherein said palindromic sequence is flanked at its 5' end by a poly G stretch
and wherein
said palindromic sequence is flanked at its 3' end by a poly G stretch,
wherein preferably said
palindromic sequence is GACGATCGTC (SEQ ID NO:2). Very preferred
oligonucleotides
comprise a palindromic sequence, wherein said palindromic sequence is flanked
at its 5' end
by at least 3 to 15, preferably by 6 to 10 guanosine entities and wherein said
palindromic
CA 03096311 2020-10-06
WO 2019/197965
PCT/IB2019/052867
sequence is flanked at its 3' end at least 3 to 15, preferably by 6 to 10,
guanosine entities,
wherein preferably said palindromic sequence is GACGATCGTC (SEQ ID NO:2).
Poly G stretch: The term poly G stretch relates to a segment of an
oligonucleotide,
wherein said segment consists of at least 3 consecutive guanosine residues.
Preferred poly G
5
stretches consist of 3 to 25, preferably of 4 to 20, more preferably of 4 to
15 and most
preferably of 4 to 10 consecutive guanosine entities. Further preferred poly G
stretches consist
of 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20
consecutive guanosine
entities.
CpG motif: As used herein, the term CpG motif refers to short DNA sequence,
10 preferably a single stranded DNA sequence, comprising a cytosine (C) -
guanosine (G)
dinucleotide, wherein C is unmethylated and wherein preferably said CG
dinucleotide is
phosphodiester bound. Preferably, a CpG motif comprises at least one,
preferably one, two or
three, additional nucleotides 5' and/or 3' of said CG dinucleotide, wherein
further preferably
said additional nucleotides do not comprise a CG dinucleotide.
15
Relative peak start time: The term "relative peak start time" is a parameter
which is
indicative of the aggregation state of an oligonucleotide and which was
analyzed essentially
as described in WO 2007/144150 by analytical size exclusion HPLC using the
conditions as
described in Example 4.
Packaged: The term "packaged" as used herein refers to the state of an
oligonucleotide,
typically and preferably of aggregated oligonucleotides, in relation to the
virus-like particle.
The use of the terms "aggregated oligonucleotides packaged into VLP" or "VLP
packaged
with aggregated oligonucleotides" is equivalent. The term "packaged" as used
herein typically
and preferably refers to non-covalent binding, preferably to ionic
interactions, hydrophobic
interactions, or hydrogen bonds. Typically and very preferably, the term
"packaged" as used
herein refers to the encapsulation of said aggregated oligonucleotides within
the VLP.
Typically and preferably, a VLP packaged with aggregated oligonucleotides
protects said
aggregated oligonucleotides from degradation, preferably from DNAse
hydrolysis. Therefore,
in the preferred meaning, the term "packaged" indicates that the aggregated
oligonucleotides
in a packaged state are not accessible to DNAse hydrolysis. More preferably,
the term
"packaged" indicates that the aggregated oligonucleotides are not accessible
to DNAse
hydrolysis, wherein further preferably the DNAse is DNAseI or Benzonase. Still
more
preferably, the term "packaged" indicates that the aggregated oligonucleotides
are not
accessible to Benzonase hydrolysis.
CA 03096311 2020-10-06
WO 2019/197965
PCT/IB2019/052867
16
The accessibility of the oligonucleotide for DNAse (e.g. DNaseI or Benzonase)
is
preferably assayed as described in Examples 11-17 of W02003/024481A2 (see p.
111
therein). In a preferred meaning, a VLP is regarded as being packaged with an
oligonucleotide, when after treatment with Benzonase (190 U Benzonase / mg
coat protein in
a buffer comprising 2 mM MgCl2, pH 7.2, 20-25 C, 18 h) at least 90 %,
preferably at least 95
%, most preferably at least 98 % of said oligonucleotide can be recovered from
said VLP (e.g.
in an ethidiumbromide stained gel). It is apparent for the artisan that such
assays require
appropriate controls and may need to be adapted to the specific combination of
VLP and
oligonucleotide. In a very preferred meaning, oligonucleotide G10 (SEQ ID
NO:1) is
regarded as being packaged into a VLP of an RNA bacteriophage Q(3, when after
treatment
with Benzonase (190 U Benzonase / mg coat protein in a buffer comprising 2 mM
MgCl2 , pH
7.2, 20-25 C, 18 h) at least 90 %, preferably at least 95 %, most preferably
at least 98 % of
said G10 can be recovered from said VLP of RNA bacteriophage Q(3.
Coat protein: As used herein, the term "coat protein" refers to the protein(s)
of a RNA
bacteriophage capable of being incorporated within the capsid assembly of the
bacteriophage
or the RNA bacteriophage. Thus, the term coat protein refers to the protein
forming the capsid
of a RNA bacteriophage or a VLP of a RNA bacteriophage. Typically and
preferably, coat
protein of RNA bacteriophages has a dimeric structure.
Fragment of a recombinant coat protein: Fragment of a recombinant coat
protein, as
used herein, is defined as a polypeptide, which is of at least 70%, preferably
at least 80%,
more preferably at least 90%, even more preferably at least 95% the length of
the wild-type
coat protein, or wild type recombinant protein, respectively and which
preferably retains the
capability of forming VLP. Preferably the fragment is obtained by at least one
internal
deletion, at least one truncation or at least one combination thereof. The
term "fragment of a
recombinant coat protein" or "fragment of a coat protein" shall further
encompass
polypeptide, which has at least 80 %, preferably 90 %, even more preferably 95
% amino acid
sequence identity with the wildtype coat protein, respectively, and which is
preferably capable
of assembling into a virus-like particle. The term "mutant coat protein"
refers to a polypeptide
having an amino acid sequence derived from the wild type recombinant protein,
or coat
protein, respectively, wherein the amino acid sequence is at least 80%,
preferably at least
85%, 90%, 95%, 97%, or 99% identical to the wild type sequence and preferably
retains the
ability to assemble into a VLP.
CA 03096311 2020-10-06
WO 2019/197965
PCT/IB2019/052867
17
Virus-like particle (VLP): VLP as used herein, refers to a non-replicative or
non-
infectious, preferably a non-replicative and non-infectious virus particle, or
refers to a non-
replicative or non-infectious, preferably a non-replicative and non-infectious
structure
resembling a virus particle, preferably a capsid of a virus. The term "non-
replicative", as used
herein, refers to being incapable of replicating the genome comprised by the
VLP. The term
"non-infectious", as used herein, refers to being incapable of entering the
host cell. Preferably
a virus-like particle in accordance with the invention is non-replicative
and/or non-infectious
since it lacks all or part of the viral genome or genome function. In one
embodiment, a virus-
like particle is a virus particle, in which the viral genome has been
physically or chemically
inactivated, removed by disassembly and reassembly, or by assembly of purified
proteins into
a VLP. Typically and more preferably a virus-like particle lacks all or part
of the replicative
and infectious components of the viral genome. A virus-like particle in
accordance with the
invention may contain nucleic acid distinct from their genome. A typical and
preferred
embodiment of a virus-like particle in accordance with the present invention
is a viral capsid
such as the viral capsid of the corresponding virus, bacteriophage, preferably
RNA
bacteriophage. The term "capsid", refers to a macromolecular assembly composed
of viral
protein subunits. Typically, there are 60, 120, 180, 240, 300, 360 and more
than 360 viral
protein subunits. Typically and preferably, the interactions of these subunits
lead to the
formation of viral capsid with an inherent repetitive organization, wherein
said structure
typically and preferably is spherical. For example, the capsids of RNA
bacteriophages have a
spherical form of icosahedral symmetry.
Virus-like particle of an RNA bacteriophage: As used herein, the term "virus-
like
particle of a RNA bacteriophage" refers to a virus-like particle comprising,
or preferably
consisting essentially of or consisting of coat proteins, mutants or fragments
thereof, of a
RNA bacteriophage. In addition, virus-like particle of a RNA bacteriophage
resembling the
structure of a RNA bacteriophage, being non replicative and/or non-infectious,
and lacking at
least the gene or genes encoding for the replication machinery of the RNA
bacteriophage, and
typically also lacking the gene or genes encoding the protein or proteins
responsible for viral
attachment to or entry into the host. Preferred VLPs derived from RNA
bacteriophages
exhibit icosahedral symmetry and consist of 180 subunits. In the context of
the invention the
term virus-like particle of an RNA bacteriophage preferably relates to a
macromolecular
structure obtained by the self-assembly of recombinant coat protein of an RNA
bacteriophage,
CA 03096311 2020-10-06
WO 2019/197965
PCT/IB2019/052867
18
or fragments or mutants thereof, wherein preferably said self-assembly took
place in the
presence of oligonucleotide and aggregated oligonucleotides, respectively.
Agent capable of preventing the self assembly of coat protein: An agent
capable of
preventing the self assembly of coat protein is an agent which prevents the
spontaneous
formation of virus-like particles in said mixture. The artisan is able to
determine the chemical
nature and the appropriate concentration of said agent experimentally, e.g. by
analyzing said
mixture by size exclusion chromatography, as for example disclosed in Example
9 of
W02007/144150. An agent is capable of preventing the self assembly of coat
protein, when
after incubation of said mixture for at least 1 h at room temperature,
preferably at 22 C, no
virus-like particle is detectable by the size exclusion chromatography, as for
example
disclosed in Example 9 of W02007/144150. However, agent which is capable of
preventing
the self assembly of coat protein, does not irreversibly modify said coat
protein and removing
said agent from said mixture will result in the spontaneous formation of virus-
like particles.
Preferred agents capable of preventing the self assembly of coat protein
comprise detergents,
guanidinium hydrochloride and urea, most preferably urea. Preferred detergents
are sodium
dodecyl sulfate, Tween 20, TritonX 100 and the like. Typically and preferably
agents capable
of preventing the self assembly of coat protein further comprise a reducing
agent such as
typically and preferably DDT which keeps intermolecular disulfide bounds
formed by
cysteine residues of said coat protein in a reduced state.
Purity: The purity of a composition of the invention comprising (i) a virus-
like particle,
wherein said virus-like particle is a virus-like particle of an RNA
bacteriophage, and (ii)
aggregated oligonucleotides, wherein said aggregated oligonucleotides are
packaged into said
virus-like particle, is determined by analytic size exclusion HPLC, wherein
said HPLC is
performed under conditions essentially, preferably exactly as disclosed in
Example 4. The
purity of said composition is determined as the percentage of the peak area of
said virus-like
particle contained in said composition relative to the total peak area of all
peaks of the same
chromatogram.
One", "a/an": When the terms "one," "a," or "an" are used in this disclosure,
they mean
"at least one" or "one or more," unless otherwise indicated.
About: within the meaning of the present application the expression about
shall have the
meaning of +/- 4 %, typically and preferably of +/- 2 %. For example about 100
shall mean 96
to 104, typically and preferably 98 to 102.
The present invention provides for a process for producing a nucleotide
composition
CA 03096311 2020-10-06
WO 2019/197965
PCT/IB2019/052867
19
comprising aggregated oligonucleotides said process comprising the steps of:
(a) providing
oligonucleotides, wherein said oligonucleotides comprise at least one poly G
stretch; (b)
denaturing said oligonucleotides, wherein said denaturing comprises the step
of (i)
incubating an aqueous solution I comprising said oligonucleotides and a
chaotropic agent at
a temperature I until the average diameter of said oligonucleotides is 1 nm or
less, wherein
preferably said average diameter is determined by Dynamic Light Scattering
(DLS), and
wherein said temperature I is 75 C to 99 C, and wherein preferably said
chaotropic agent is
urea; (c) aggregating said oligonucleotides, wherein said aggregating
comprises the steps of
(i) incubating an aqueous solution II comprising said oligonucleotides having
said average
diameter of 1 nm or less obtained in step (b), a chaotropic agent and a cation
at a
temperature II to form said aggregated oligonucleotides, wherein said
incubating is
performed until the average diameter of said formed aggregated
oligonucleotides is 6-16
nm, wherein preferably said average diameter is determined by Dynamic Light
Scattering
(DLS), and wherein said temperature II is 75 C to 99 C, and wherein preferably
said
chaotropic agent is urea; (ii) adjusting the temperature of said solution II
to a temperature
III, wherein said temperature III is below 40 C, preferably below 30 C;
wherein said steps
are preferably performed in the given order.
The present invention further provides a process for producing aggregated
oligonucleotides, wherein said process comprises the steps of: (a) providing
oligonucleotides, wherein said oligonucleotides comprise at least one poly G
stretch; (b)
denaturing said oligonucleotides, wherein said denaturing comprises the step
of (i)
incubating an aqueous solution I comprising said oligonucleotides and a
chaotropic agent at
a temperature I until the average diameter of said oligonucleotides is 1 nm or
less, wherein
preferably said average diameter is determined by Dynamic Light Scattering
(DLS), and
wherein said temperature I is 75 C to 99 C, and wherein preferably said
chaotropic agent is
urea; (c) aggregating said oligonucleotides, wherein said aggregating
comprises the steps of
(i) incubating an aqueous solution II comprising said oligonucleotides having
said average
diameter of 1 nm or less obtained in step (b), a chaotropic agent and a cation
at a
temperature II to form said aggregated oligonucleotides, wherein said
incubating is
performed until the average diameter of said formed aggregated
oligonucleotides is 6-16
nm, wherein preferably said average diameter is determined by Dynamic Light
Scattering
(DLS), and wherein said temperature II is 75 C to 99 C, and wherein preferably
said
chaotropic agent is urea; (ii) adjusting the temperature of said solution II
to a temperature
CA 03096311 2020-10-06
WO 2019/197965
PCT/IB2019/052867
III, wherein said temperature III is below 40 C, preferably below 30 C;
wherein said steps
are preferably performed in the given order.
In a preferred embodiment, said denaturing said oligonucleotides comprises the
step
of solubilizing said oligonucleotides in an aqueous solution comprising said
chaotropic
5 agent to form said aqueous solution I, wherein said aqueous solution does
not comprise
mono or divalent ions in a concentration higher than 1 mM, and wherein
preferably said
aqueous solution does not comprise mono or divalent ions in a concentration
higher than
500 M, preferably not higher than 250 M, preferably not higher than 100 M,
preferably
not higher than 50 M, preferably not higher than 10 M.
10 In a further preferred embodiment, said denaturing said oligonucleotides
comprises the
step of solubilizing said oligonucleotides in an aqueous solution comprising
said chaotropic
agent to form said aqueous solution I, wherein said aqueous solution does not
comprise mono
or divalent ions in a concentration which after the addition of the
oligonucleotide would cause
said oligonucleotides self-aggregate.
15 In a further preferred embodiment, said aqueous solution I does not
comprise mono or
divalent ions in a concentration such that said oligonucleotides self-
aggregate.
In a further preferred embodiment, said denaturing said oligonucleotides
comprises the
step of solubilizing said oligonucleotides in an aqueous solution comprising
said chaotropic
agent to form said aqueous solution I, wherein said aqueous solution does not
comprise mono
20 or divalent ions in a concentration which after the addition of the
oligonucleotide would cause
said oligonucleotides spontaneously self-aggregate.
In a further preferred embodiment, said aqueous solution I does not comprise
mono or
divalent ions in a concentration such that said oligonucleotides spontaneously
self-aggregate.
In a further preferred embodiment, said denaturing said oligonucleotides
comprises the
step of solubilizing said oligonucleotides and said chaotropic agent to form
said aqueous
solution I, and adjusting the temperature of said solution Ito temperature I.
In a further preferred embodiment, said chaotropic agent comprised in said
solution I is
selected from urea, phenol, isopropyl alcohol, ethanol and guanidinium
chloride.
In a further preferred embodiment, said chaotropic agent comprised in said
solution I is
urea.
In a further preferred embodiment, said temperature I is 75 C to 90 C,
preferably 80 C
to 90 C, further preferably 83 C to 87 C, again further preferably about 85 C,
and most
preferably 85 C.
CA 03096311 2020-10-06
WO 2019/197965
PCT/IB2019/052867
21
In a further preferred embodiment, said incubating said oligonucleotide in
said solution
I at said temperature I is performed for 10 to 120 min, preferably for 20 to
60 min, further
preferably for 20 to 30 min, and again further preferably for 15-18 min.
In a further preferred embodiment, said concentration of said chaotropic
agent,
preferably said urea, in said solution I is 200nM to 5M, preferably 500mM to
2M, further
preferably 500mM to 1.5M, and again further preferably 1M.
In a further preferred embodiment, said concentration of said
oligonucleotides,
preferably said oligonucleotides of SEQ ID NO:1, in said solution I is 10004
to 1mM,
preferably 10004 to 75004, further preferably 20004 to 60004, and again
further
preferably 350 M to 500 M.
In a further preferred embodiment, said incubating said oligonucleotides in
said solution
I at said temperature I is performed between 15 minutes and 120 minutes,
preferably between
min to 60 min, and further preferably between 15 min to 30 min, again further
preferably
between 15 min to 25 min.
15 In
a further preferred embodiment, said oligonucleotides comprise at its 5' end
at least 3
and at most 15 guanosine entities and at its 3' end at least 3 and at most 15
guanosine entities,
preferably at least 6 and at most 13 guanosine entities and at its 3' end at
least 6 and at most
13 guanosine entities, further preferably at least 8 and at most 11 guanosine
entities and at its
3' end at least 8 and at most 11 guanosine entities.
In a further preferred embodiment, said oligonucleotides comprise a
palindromic
sequence, wherein preferably said palindromic sequence is GACGATCGTC (SEQ ID
NO:2),
and wherein further preferably said palindromic sequence is flanked at its 5'
end by at least 3
and at most 15 guanosine entities and wherein said palindromic sequence is
flanked at its 3'
end by at least 3 and at most 15 guanosine entities, and wherein again further
preferably said
palindromic sequence is flanked at its 5' end by at least 6 and at most 13
guanosine entities
and wherein said palindromic sequence is flanked at its 3' end by at least 6
and at most 13
guanosine entities, and wherein again further preferably said palindromic
sequence is flanked
at its 5' end by at least 8 and at most 11 guanosine entities and wherein said
palindromic
sequence is flanked at its 3' end by at least 8 and at most 11 guanosine
entities.
In a further preferred embodiment, said oligonucleotides comprises 10 to 1000
nucleotides, preferably 10 to 200 nucleotides, further preferably 10 to 100
nucleotides, still
further preferably 20 to 40 nucleotides, and still further preferably 30
nucleotides.
CA 03096311 2020-10-06
WO 2019/197965
PCT/IB2019/052867
22
In a further preferred embodiment, said oligonucleotides comprise the nucleic
acid
sequence selected from the group consisting of:
(a) G10: GGGGGGGGGGGACGATCGTCGGGGGGGGGG (SEQ ID NO:1);
(b) G10-11: GGGGGGGGGGGACGATCGTCGGGGGGGGGGG (SEQ ID NO:3);
(c) G12-11: GGGGGGGGGGGGGACGATCGTCGGGGGGGGGGG (SEQ ID NO:4)
(d) G6: GGGGGGGACGATCGTCGGGGGG (SEQ ID NO:5);
(e) G7: GGGGGGGGACGATCGTCGGGGGGG (SEQ ID NO:6);
(f) G8: GGGGGGGGGACGATCGTCGGGGGGGG (SEQ ID NO:7);
(g) G9: GGGGGGGGGGACGATCGTCGGGGGGGGG (SEQ ID NO:8);
(h) G11: GGGGGGGGGGGGACGATCGTCGGGGGGGGGGG (SEQ ID NO:9)
(i) G6-10: GGGGGGGACGATCGTCGGGGGGGGGG (SEQ ID NO:24);
(j) G7-10: GGGGGGGGACGATCGTCGGGGGGGGGG (SEQ ID NO:25);
(k) G8-10: GGGGGGGGGACGATCGTCGGGGGGGGGG (SEQ ID NO:26); and
(1) G9-10: GGGGGGGGGGACGATCGTCGGGGGGGGGG (SEQ ID NO:27).
In a further preferred embodiment, said oligonucleotides have the nucleic acid
sequence
G10 GGGGGGGGGGGACGATCGTCGGGGGGGGGG (SEQ ID NO:1).
In a further preferred embodiment, said oligonucleotides exclusively consists
of
phosphodiester connected deoxynucleotides.
In a further preferred embodiment, the purity of said oligonucleotides,
preferably the
purity of said oligonucleotides of SEQ ID NO:1, is 90% or higher, as
determined by HPLC,
preferably by reverse phase HPLC or anion Exchange HPLC, more preferably by
reverse
phase HPLC.
In a further preferred embodiment, the purity of said oligonucleotides,
preferably the
purity of said oligonucleotides of SEQ ID NO:1, is 92% or higher, preferably
94% or higher,
further preferably 95% or higher, again further preferably 97% or higher,
again further
preferably 98% or higher, again further preferably 99% or higher, as
determined by HPLC,
preferably by reverse phase HPLC or anion Exchange HPLC, more preferably by
reverse
phase HPLC.
In a further preferred embodiment, said oligonucleotides comprise the sequence
of SEQ
ID NO:1, wherein said oligonucleotides exclusively consists of phosphodiester
connected
deoxynucleotides.
In a further preferred embodiment, said oligonucleotides consists of the
sequence of
SEQ ID NO:l.
CA 03096311 2020-10-06
WO 2019/197965
PCT/IB2019/052867
23
In a further preferred embodiment, said oligonucleotides consists of the
sequence of
SEQ ID NO:1, wherein said oligonucleotides exclusively consists of
phosphodiester
connected deoxynucleotides.
In a further preferred embodiment, said chaotropic agent comprised in said
solution II is
.. selected from urea, phenol, isopropyl alcohol, ethanol and guanidinium
chloride.
In a further preferred embodiment, said chaotropic agent comprised in said
solution II is
urea.
Thus, in a further preferred embodiment, said chaotropic agent comprised in
said
solution II, i.e. in said solution for aggregation, is urea.
In a further preferred embodiment, said temperature II is 75 C to 90 C,
preferably
80 C to 90 C, further preferably 83 C to 87 C, again further preferably about
85 C, and
most preferably 85 C.
In a further preferred embodiment, said concentration of said chaotropic
agent,
preferably said urea, in said solution II is 200nM to 5M, preferably 500mM to
2M, further
preferably 500mM to 1.5M, and again further preferably 1M.
In a further preferred embodiment, said cation is selected from Nat, Kt, NH4,
Lit, Ca2+,
Mg2+ and Zn2t.
Said cation is typically and preferably provided by way of an inorganic salt,
and
wherein further preferably said inorganic salt are selected from chlorides and
sulfates.
.. Preferably, said Nat, Kt, NH4, Lit, Ca2+, Mg2+ , Zn2+ as said cation are
provided by its
chloride salt. Alternatively, said Nat, Kt, NH4, Lit, Ca2+, Mg2+ , Zn2+ as
said cation are
provided by its sulfate salt. Again further preferably, said Nat, Kt, NH4,
Lit, Ca2+, Mg2+ as
said cation are provided by its chloride salt, wherein said Zn2+ as said
cation is preferably
provided as its sulfate salt.
In a further preferred embodiment, said the concentration of said cation in
said solution
II is 20mM to 2M, preferably 50m1v1 to 1M, further preferably 100mM to 500mM,
and again
further preferably 250mM.
In a further preferred embodiment, said chaotropic agent comprised in said
solution I
and said chaotropic agent comprised in said solution II is the same.
In a further preferred embodiment, the concentration of said chaotropic agent
comprised
in said solution I and said chaotropic agent comprised in said solution II is
the same.
In a further preferred embodiment, said chaotropic agent comprised in said
solution I
and said chaotropic agent comprised in said solution II is urea.
CA 03096311 2020-10-06
WO 2019/197965
PCT/IB2019/052867
24
In a further preferred embodiment, said aggregating said oligonucleotides
comprises the
steps of (i) solubilizing said chaotropic agent and said cation to form an
aqueous solution Ha,
(ii) mixing said aqueous solution Ha and said aqueous solution I comprising
said
oligonucleotides having said average diameter of 1 nm or less obtained in step
(b) to form
said aqueous solution II, and (iii) adjusting the temperature of said solution
II to temperature
II.
In a further preferred embodiment, the difference of temperature of said
temperature I
and said temperature II is 5 C or less, preferably 4 C or less, further
preferably 3 C or less,
again further preferably 2 C or less, again further preferably 1 C or less,
and most preferably
said temperature I and said temperature II are equal.
In a further preferred embodiment, said incubating is performed until the
average
diameter of said aggregated oligonucleotides is 7-14 nm, wherein said average
diameter is
determined by Dynamic Light Scattering (DLS).
In a further preferred embodiment, said incubating is performed until the
average
diameter of said aggregated oligonucleotides is 8-14 nm, wherein said average
diameter is
determined by Dynamic Light Scattering (DLS).
In a further preferred embodiment, said incubating is performed until the
average
diameter of said aggregated oligonucleotides is 9-14 nm, wherein said average
diameter is
determined by Dynamic Light Scattering (DLS).
In a further preferred embodiment, said incubating is performed until the
average
diameter of said aggregated oligonucleotides is 10-14 nm, wherein said average
diameter is
determined by Dynamic Light Scattering (DLS).
In a further preferred embodiment, said incubating is performed until the
average
diameter of said aggregated oligonucleotides is 11-13 nm, wherein said average
diameter is
determined by Dynamic Light Scattering (DLS).
In a further preferred embodiment, said incubating is performed until the
average
diameter of said aggregated oligonucleotides is 11, 12 or 13 nm, wherein
average said
diameter is determined by Dynamic Light Scattering (DLS).
In a further preferred embodiment, said incubating is performed until the
average
diameter of said aggregated oligonucleotides is 12 nm, wherein said average
diameter is
determined by Dynamic Light Scattering (DLS).
The determination of the average diameter by Dynamic Light Scattering (DLS) in
accordance with the present invention, be it that of said oligonucleotides in
the course of the
CA 03096311 2020-10-06
WO 2019/197965
PCT/IB2019/052867
denaturing, or be it that of said aggregated oligonucleotides in the course of
the aggregation,
is highly beneficial since said determinations can be easily effected while
the process is
running. This further ensures a very high precision and very high control of
the desired size of
the oligonucleotides and aggregated oligonucleotides, respectively.
5 In
a further preferred embodiment, said incubating is performed until said
aggregated
oligonucleotides comprise a relative peak start time of 80 to 110 %, where
said relative peak
start time is determined by size exclusion HPLC with the capsid of an RNA
bacteriophage as
the standard.
In a further preferred embodiment, said process further comprises the step of
purifying
10
said aggregated oligonucleotides, and wherein preferably said purifying
comprises filtering
said aggregated oligonucleotides, preferably said solution II comprising said
aggregated
oligonucleotides, through a 50 nm filter.
In a further preferred embodiment, said 50 nm filter is a 50 nm PTFE filter.
In a further preferred embodiment, said filtering said aggregated
oligonucleotides,
15
preferably said solution II comprising said aggregated oligonucleotides,
through said 50 nm
filter, preferably said 50 nm PTFE filter, is performed at 0 C-20 C.
Said further preferred step of purifying, preferably filtering, allows to
remove any large
aggregates prior to the packaging step into the VLPs and, thus, further leads
typically to an
even further increase in purity of the final product, i.e. the inventive VLPs
packaged with the
20
aggregated oligonucleotides by typically around 5%. The increase in purity is,
thus, typically
associated with a decrease in higher molecular weight material in the final
product as
evidenced by SEC HLPC or DLS.
In a further preferred embodiment, said process does not comprise a step of
purifying
said aggregated oligonucleotides.
25 In
a further preferred embodiment, said aggregated oligonucleotides comprise at
its 5'
end at least 3 and at most 15 guanosine entities and at its 3' end at least 3
and at most 15
guanosine entities, preferably at least 6 and at most 13 guanosine entities
and at its 3' end at
least 6 and at most 13 guanosine entities, further preferably at least 8 and
at most 11
guanosine entities and at its 3' end at least 8 and at most 11 guanosine
entities.
In a further preferred embodiment, said aggregated oligonucleotides comprise a
palindromic sequence, wherein preferably said palindromic sequence is
GACGATCGTC
(SEQ ID NO:2), and wherein further preferably said palindromic sequence is
flanked at its 5'
end by at least 3 and at most 15 guanosine entities and wherein said
palindromic sequence is
CA 03096311 2020-10-06
WO 2019/197965
PCT/IB2019/052867
26
flanked at its 3' end by at least 3 and at most 15 guanosine entities, and
wherein again further
preferably said palindromic sequence is flanked at its 5' end by at least 6
and at most 13
guanosine entities and wherein said palindromic sequence is flanked at its 3'
end by at least 6
and at most 13 guanosine entities, and wherein again further preferably said
palindromic
sequence is flanked at its 5' end by at least 8 and at most 11 guanosine
entities and wherein
said palindromic sequence is flanked at its 3' end by at least 8 and at most
11 guanosine
entities.
In a further preferred embodiment, said aggregated oligonucleotides comprises
10 to
1000 nucleotides, preferably 10 to 200 nucleotides, further preferably 10 to
100 nucleotides,
still further preferably 20 to 40 nucleotides, and still further preferably 30
nucleotides.
In a further preferred embodiment, said aggregated oligonucleotides comprise a
nucleic
acid sequence selected from the group consisting of:
(a) G10: GGGGGGGGGGGACGATCGTCGGGGGGGGGG (SEQ ID NO:1);
(b) G10-11: GGGGGGGGGGGACGATCGTCGGGGGGGGGGG (SEQ ID NO:3);
(c) G12-11: GGGGGGGGGGGGGACGATCGTCGGGGGGGGGGG (SEQ ID NO:4)
(d) G6: GGGGGGGACGATCGTCGGGGGG (SEQ ID NO:5);
(e) G7: GGGGGGGGACGATCGTCGGGGGGG (SEQ ID NO:6);
(f) G8: GGGGGGGGGACGATCGTCGGGGGGGG (SEQ ID NO:7);
(g) G9: GGGGGGGGGGACGATCGTCGGGGGGGGG (SEQ ID NO:8);
(h) G11: GGGGGGGGGGGGACGATCGTCGGGGGGGGGGG (SEQ ID NO:9)
(i) G6-10: GGGGGGGACGATCGTCGGGGGGGGGG (SEQ ID NO:24);
(j) G7-10: GGGGGGGGACGATCGTCGGGGGGGGGG (SEQ ID NO:25);
(k) G8-10: GGGGGGGGGACGATCGTCGGGGGGGGGG (SEQ ID NO:26); and
(1) G9-10: GGGGGGGGGGACGATCGTCGGGGGGGGGG (SEQ ID NO:27).
In a further preferred embodiment, said aggregated oligonucleotides have the
nucleic
acid sequence GGGGGGGGGGGACGATCGTCGGGGGGGGGG (SEQ ID NO:1) (G10).
In a further preferred embodiment, said aggregated oligonucleotides
exclusively
consists of phosphodiester connected deoxynucleotides.
In a further aspect, the present invention provides for a nucleotide
composition
comprising aggregated oligonucleotides, wherein said nucleotide composition is
obtainable by
the process for producing a nucleotide composition comprising aggregated
oligonucleotides in
accordance with the present invention, wherein preferably said aggregated
oligonucleotides
CA 03096311 2020-10-06
WO 2019/197965
PCT/IB2019/052867
27
have an average diameter of 6-16nm, preferably 7-14 nm, wherein said average
diameter is
determined by Dynamic Light Scattering (DLS).
In a preferred embodiment, said aggregated oligonucleotides have an average
diameter
of 8-14 nm, preferably 9-14 nm, further preferably 10-14 nm, wherein said
average diameter
is determined by Dynamic Light Scattering (DLS).
In a further preferred embodiment, said aggregated oligonucleotides have an
average
diameter of 11-13 nm, preferably 11, 12 or 13 nm, further preferably 12 nm,
wherein said
average diameter is determined by Dynamic Light Scattering (DLS).
In a further preferred embodiment, at least 90%, preferably at least 95%, of
said
aggregated oligonucleotides have a diameter of 10.8 nm to 13.2 nm, wherein
said diameter is
determined by Dynamic Light Scattering (DLS).
In a further preferred embodiment, said at least 65%, preferably at least 70%
of said
aggregated oligonucleotides have a diameter of 11.4 nm to 12.6 nm, wherein
said diameter is
determined by Dynamic Light Scattering (DLS).
In a further preferred embodiment of said nucleotide composition, at least
90%,
preferably at least 95%, of said aggregated oligonucleotides have a diameter
of 12 nm 10%,
i.e. have a diameter of 10.8 nm to 13.2 nm, wherein said diameter is
determined by Dynamic
Light Scattering (DLS).
In a further preferred embodiment of said nucleotide composition, wherein at
least 65%,
preferably at least 70% of said aggregated oligonucleotides have a diameter of
12nm 5%,
i.e. have a diameter of 11.4 nm to 12.6 nm, wherein said diameter is
determined by Dynamic
Light Scattering (DLS).
In a further preferred embodiment, said aggregated oligonucleotides have the
nucleic
acid sequence G10 GGGGGGGGGGGACGATCGTCGGGGGGGGGG (SEQ ID NO:1).
In a further preferred embodiment, said aggregated oligonucleotides have the
nucleic
acid sequence G10 GGGGGGGGGGGACGATCGTCGGGGGGGGGG (SEQ ID NO:1), and
wherein said aggregated oligonucleotides exclusively consists of
phosphodiester connected
deoxynucleotides.
In an again further aspect, the present invention provides for a nucleotide
composition
comprising aggregated oligonucleotides, wherein said aggregated
oligonucleotides have an
average diameter of 7-14 nm, wherein said average diameter is determined by
Dynamic Light
Scattering (DLS).
CA 03096311 2020-10-06
WO 2019/197965
PCT/IB2019/052867
28
In a preferred embodiment, said aggregated oligonucleotides have an average
diameter
of 8-14 nm, preferably 9-14 nm, further preferably 10-14 nm, wherein said
average diameter
is determined by Dynamic Light Scattering (DLS).
In a further preferred embodiment, said aggregated oligonucleotides have an
average
diameter of 11-13 nm, preferably 11, 12 or 13 nm, further preferably 12 nm,
wherein said
average diameter is determined by Dynamic Light Scattering (DLS).
In a further preferred embodiment, wherein at least 90%, preferably at least
95%, of
said aggregated oligonucleotides have a diameter of 10.8 nm to 13.2 nm,
wherein said
diameter is determined by Dynamic Light Scattering (DLS).
In a further preferred embodiment, wherein at least 65%, preferably at least
70% of said
aggregated oligonucleotides have a diameter of 11.4 nm to 12.6 nm, wherein
said diameter is
determined by Dynamic Light Scattering (DLS).
In a further preferred embodiment of said nucleotide composition, at least
90%,
preferably at least 95%, of said aggregated oligonucleotides have a diameter
of 12 nm 10%,
i.e. have a diameter of 10.8 nm to 13.2 nm, wherein said diameter is
determined by Dynamic
Light Scattering (DLS).
In a further preferred embodiment of said nucleotide composition, wherein at
least 65%,
preferably at least 70% of said aggregated oligonucleotides have a diameter of
12nm 5%,
i.e. have a diameter of 11.4 nm to 12.6 nm, wherein said diameter is
determined by Dynamic
Light Scattering (DLS).
In a further preferred embodiment, said aggregated oligonucleotides have the
nucleic
acid sequence G10 GGGGGGGGGGGACGATCGTCGGGGGGGGGG (SEQ ID NO:1).
In a further preferred embodiment, said aggregated oligonucleotides have the
nucleic
acid sequence G10 GGGGGGGGGGGACGATCGTCGGGGGGGGGG (SEQ ID NO:1), and
wherein said aggregated oligonucleotides exclusively consists of
phosphodiester connected
deoxynucleotides.
In a further aspect, the present invention provides for a process for
producing a
composition comprising (i) a virus-like particle, wherein said virus-like
particle is a virus-
like particle of an RNA bacteriophage, and (ii) aggregated oligonucleotides,
wherein said
aggregated oligonucleotides are packaged into said virus-like particle, said
process
comprising the steps of: (a) generating a mixture, wherein said mixture
comprises: (i) a coat
protein of said RNA bacteriophage; (ii) an agent capable of preventing the
self-assembly of
said coat protein; and (iii) aggregated oligonucleotides, wherein said
aggregated
CA 03096311 2020-10-06
WO 2019/197965
PCT/IB2019/052867
29
oligonucleotides comprise oligonucleotides comprising at least one poly G
stretch, and
wherein said aggregated oligonucleotides have an average diameter of 6-16 nm,
wherein
preferably said average diameter is determined by Dynamic Light Scattering
(DLS); (b)
removing said agent from said mixture; and (c) allowing said coat protein to
self-assemble
into a virus-like particle and to package said aggregated oligonucleotides.
In an again further aspect, the present invention provides for a process for
producing
a composition comprising (i) a virus-like particle, wherein said virus-like
particle is a virus-
like particle of an RNA bacteriophage, and (ii) aggregated oligonucleotides,
wherein said
aggregated oligonucleotides are packaged into said virus-like particle, said
process
comprising the steps of: (a) generating a mixture, wherein said mixture
comprises: (i) a coat
protein of said RNA bacteriophage; (ii) an agent capable of preventing the
self-assembly of
said coat protein; and (iii) aggregated oligonucleotides, wherein said
aggregated
oligonucleotides comprise oligonucleotides comprising at least one poly G
stretch, and
wherein said aggregated oligonucleotides are obtainable by the process
according to the
first aspect of the present invention, and wherein said aggregated
oligonucleotides have an
average diameter of 6-16 nm, wherein preferably said average diameter is
determined by
Dynamic Light Scattering (DLS); (b) removing said agent from said mixture; and
(c)
allowing said coat protein to self-assemble into a virus-like particle and to
package said
aggregated oligonucleotides.
In an again further aspect, the present invention provides for a process for
producing
a composition comprising (i) a virus-like particle, wherein said virus-like
particle is a virus-
like particle of an RNA bacteriophage, and (ii) aggregated oligonucleotides,
wherein said
aggregated oligonucleotides are packaged into said virus-like particle, said
process
comprising the steps of: (a) generating a mixture, wherein said mixture
comprises: (i) a coat
protein of said RNA bacteriophage; (ii) an agent capable of preventing the
self-assembly of
said coat protein; and (iii) the nucleotide composition, wherein said
nucleotide composition
is obtainable by the process for producing a nucleotide composition comprising
aggregated
oligonucleotides in accordance with the present invention, and wherein said
nucleotide
composition comprises said aggregated oligonucleotides, wherein said
aggregated
oligonucleotides comprise oligonucleotides comprising at least one poly G
stretch, and
wherein said aggregated oligonucleotides have an average diameter of 6-16 nm,
wherein
preferably said average diameter is determined by Dynamic Light Scattering
(DLS); (b)
removing said agent from said mixture; and (c) allowing said coat protein to
self-assemble
CA 03096311 2020-10-06
WO 2019/197965
PCT/IB2019/052867
into a virus-like particle and to package said aggregated oligonucleotides.
During said processes said virus-like particle is formed by self-assembly of
coat protein
of said RNA bacteriophage in the presence of said aggregated oligonucleotides.
In a preferred embodiment, said aggregated oligonucleotides have an average
diameter
5 of 8-14 nm, preferably 9-14 nm, further preferably 10-14 nm, wherein said
average diameter
is determined by Dynamic Light Scattering (DLS).
In a further preferred embodiment, said aggregated oligonucleotides have an
average
diameter of 11-13 nm, preferably 11, 12 or 13 nm, further preferably 12 nm,
wherein said
average diameter is determined by Dynamic Light Scattering (DLS).
10 In a further preferred embodiment, said coat protein comprises
recombinant proteins, or
fragments thereof, that are capable of self-assembly, of a RNA bacteriophage.
In a further preferred embodiment, said coat protein consists of recombinant
proteins, or
fragments thereof, that are capable of self-assembly, of a RNA bacteriophage.
In a further preferred embodiment, said RNA bacteriophage is selected from the
group
15 consisting of:
(a) bacteriophage Q13;
(b) bacteriophage R17;
(c) bacteriophage fr;
(d) bacteriophage GA;
20 (d) bacteriophage SP;
(e) bacteriophage M52;
(f) bacteriophage M11;
(g) bacteriophage MX1;
(h) bacteriophage NL95;
25 (i) bacteriophage f2;
(j) bacteriophage PP7; and
(k) bacteriophage AP205.
In a further preferred embodiment, said RNA bacteriophage is Qf3.
In a further preferred embodiment, said coat protein comprises a sequence
selected from
30 the group consisting of:
(a) SEQ ID NO:10 (Q0 CP);
(b) a mixture of SEQ ID NO:10 and SEQ ID NO:11 (Q0 Al protein);
(c) SEQ ID NO: 12 (R17 coat protein);
CA 03096311 2020-10-06
WO 2019/197965
PCT/IB2019/052867
31
(d) SEQ ID NO: 13 (fr coat protein);
(e) SEQ ID NO:14 (GA coat protein);
(f) SEQ ID NO: 15 (SP coat protein);
(g) a mixture of SEQ ID NO:15 and SEQ ID NO:16;
(h) SEQ ID NO:17 (M52 coat protein);
(i) SEQ ID NO:18 (M11 coat protein);
(j) SEQ ID NO:19 (MXI coat protein);
(k) SEQ ID NO:20 (NL95 coat protein);
(1) SEQ ID NO:21 (f2 coat protein);
(m) SEQ ID NO:22 (PP7 coat protein); and
(n) SEQ ID NO:23 (AP205 coat protein).
In a further preferred embodiment, said coat protein comprises the sequence of
SEQ ID
NO:10 (Q0 CP).
In a further preferred embodiment, said coat protein comprises a mixture of
SEQ ID
NO:10 and SEQ ID NO:11 (Q0 Al protein).
In a further preferred embodiment, said coat protein consist of the sequence
of SEQ ID
NO:10 (Q0 CP).
In a further preferred embodiment, said coat protein consists of a mixture of
SEQ ID
NO:10 and SEQ ID NO:11 (Q0 Al protein).
In a further preferred embodiment, the concentration of said coat protein in
said mixture
is 1 to 4 mg/ml, preferably 2.5 mg/ml.
In a further preferred embodiment, the concentration of said aggregated
oligonucleotides in said mixture is 25 to 100 pM, preferably 62.5 i.i.M.
In a further preferred embodiment, said the molar ratio of said aggregated
oligonucleotides and said coat protein in said mixture is 0.5 to 1.2,
preferably 0.7.
In a further preferred embodiment, said agent comprises a denaturing compound
selected from urea and guanidinium hydrochloride.
In a further preferred embodiment, said agent comprises a denaturing compound,
wherein said denaturing compound is urea, and wherein preferably the
concentration of said
urea in said mixture is 0.25 to 7.2 M, preferably 1 M.
In a further preferred embodiment, said agent further comprises a reducing
agent.
In a further preferred embodiment, said reducing agent is DTT, wherein
preferably the
concentration of said DTT in said mixture is 1 to 25 mM, preferably 2.5 mM.
CA 03096311 2020-10-06
WO 2019/197965
PCT/IB2019/052867
32
In a further preferred embodiment, said removing of said agent from said
mixture is
performed by a first buffer exchange with a first buffer, wherein said first
buffer comprises
sodium chloride, and wherein preferably the concentration of said sodium
chloride in said
first buffer is 50 to 350 mM, preferably 250 mM.
In a further preferred embodiment, said first buffer exchange is performed
across a
membrane, wherein said membrane comprises a molecular weight cut off of 1 to
50 kD,
preferably of 5 to 30 kD, most preferably of 30 kD.
In a further preferred embodiment, said process further comprises the step of
contacting
said virus-like particle with an oxidizing agent, wherein preferably said
oxidizing agent is
selected from the group consisting of
(a) hydrogen peroxide, wherein preferably the concentration of said hydrogen
peroxide is 0.25-50 mM, preferably 2 mM;
(b) oxygen;
(c) gluthathion;
(d) Cu2+; and
(e) Fe3 .
In a further preferred embodiment, said oxygen as oxidizing agent can be
sterile filtered
air, typically and preferably sterile filtered ambient air.
In a further preferred embodiment, said process further comprises the step of
purifying
.. said virus-like particle, and wherein said purifying comprises a second
buffer exchange with a
second buffer, wherein said second buffer is a pharmaceutically acceptable
buffer.
In a further preferred embodiment, said second buffer exchange is performed
using a
membrane, wherein said membrane comprises a molecular weight cut off of 50 to
1000 kD.
In a further preferred embodiment, said second buffer exchange is performed
using a
membrane, wherein said membrane comprises a molecular weight cut off of 100 to
300 kD.
In a further preferred embodiment, said the purity of said composition is at
least 99.5 %,
preferably at least 99.6 %, more preferably at least 99.7 %, still more
preferably at least 99.8
%, and most preferably at least 99.9 % as determined by size exclusion
chromatography.
In an again further aspect, the present invention provides for a composition
comprising
(i) a virus-like particle of an RNA bacteriophage, and (ii) aggregated
oligonucleotides,
wherein said aggregated oligonucleotides are packaged into said virus-like
particle, wherein
said composition is obtainable by a process for producing a composition
comprising (i) a
CA 03096311 2020-10-06
WO 2019/197965
PCT/IB2019/052867
33
virus-like particle, wherein said virus-like particle is a virus-like particle
of an RNA
bacteriophage, and (ii) aggregated oligonucleotides in accordance with the
present invention.
In an again further aspect, the present invention provides for a composition
comprising
(i) a virus-like particle of an RNA bacteriophage, and (ii) aggregated
oligonucleotides,
wherein said aggregated oligonucleotides are packaged into said virus-like
particle, wherein
said aggregated oligonucleotides have an average diameter of 6-16, preferably
of 7-14 nm,
wherein said average diameter is determined by Dynamic Light Scattering (DLS).
In a further preferred embodiment, said RNA bacteriophage is bacteriophage
Qf3.
In a further preferred embodiment, said virus-like particle of RNA
bacteriophage Qf3
consists of coat proteins comprising the sequence of SEQ ID NO:10 (Q0 CP).
In a further preferred embodiment, said virus-like particle of RNA
bacteriophage Qf3
consists of coat proteins comprising a mixture of SEQ ID NO:10 and SEQ ID
NO:11 (Q0 Al
protein).
In a further preferred embodiment, said virus-like particle of RNA
bacteriophage Qf3
consists of coat proteins consisting of the sequence of SEQ ID NO:10 (Q0 CP).
In a further preferred embodiment, said virus-like particle of RNA
bacteriophage Qf3
consists of coat proteins consisting of a mixture of SEQ ID NO:10 and SEQ ID
NO:11 (Q0
Al protein).
In a further preferred embodiment, said aggregated oligonucleotides have the
nucleic
acid sequence G10 GGGGGGGGGG GACGATCGTC GGGGGGGGGG (SEQ ID NO:1).
In a further preferred embodiment, said aggregated oligonucleotides have the
nucleic
acid sequence G10 GGGGGGGGGGGACGATCGTCGGGGGGGGGG (SEQ ID NO:1), and
wherein said aggregated oligonucleotides exclusively consists of
phosphodiester connected
deoxynucleotides.
In a further preferred embodiment, the purity of said composition is at least
99.5 %,
preferably at least 99.6 %, more preferably at least 99.7 %, still more
preferably at least 99.8
%, and most preferably at least 99.9 % as determined by size exclusion
chromatography.
In a further preferred embodiment, said aggregated oligonucleotides have an
average
diameter of 6-16, preferably of 7-14 nm, wherein said average diameter is
determined by
Dynamic Light Scattering (DLS).
In a further preferred embodiment, said aggregated oligonucleotides have an
average
diameter of 8-14 nm, preferably 9-14 nm, further preferably 10-14 nm, wherein
said average
diameter is determined by Dynamic Light Scattering (DLS).
CA 03096311 2020-10-06
WO 2019/197965
PCT/IB2019/052867
34
In a further preferred embodiment, said aggregated oligonucleotides have an
average
diameter of 11-13 nm, preferably 11, 12 or 13 nm, further preferably 12 nm,
wherein said
average diameter is determined by Dynamic Light Scattering (DLS).
In a further preferred embodiment, wherein at least 90%, preferably at least
95%, of
said aggregated oligonucleotides have a diameter of 10.8 nm to 13.2 nm,
wherein said
diameter is determined by Dynamic Light Scattering (DLS).
In a further preferred embodiment, wherein at least 65%, preferably at least
70% of said
aggregated oligonucleotides have a diameter of 11.4 nm to 12.6 nm, wherein
said diameter is
determined by Dynamic Light Scattering (DLS).
In a further preferred embodiment of said composition, at least 90%,
preferably at least
95%, of said aggregated oligonucleotides have a diameter of 12 nm 10%, i.e.
have a
diameter of 10.8 nm to 13.2 nm, wherein said diameter is determined by Dynamic
Light
Scattering (DLS).
In a further preferred embodiment of said composition, wherein at least 65%,
preferably
at least 70% of said aggregated oligonucleotides have a diameter of 12nm 5%,
i.e. have a
diameter of 11.4 nm to 12.6 nm, wherein said diameter is determined by Dynamic
Light
Scattering (DLS).
EXAMPLES
The Examples are intended to illustrate the present invention without
restricting it. In
the Examples described below, unless otherwise indicated, all temperatures are
set forth in
degrees Celsius ( C). Reagents were purchased from commercial suppliers such
as Sigma
Aldrich, Boston Bioproducts, Invitrogen, Alfa Aesar or the like, and were used
without
further purification unless otherwise indicated. The water used in the
described reactions has
been purified or treated to remove all contaminants and salts. The removal of
inorganic ionic
impurities is confirmed by measuring the conductivity of the water. Water used
in this
application has a resistivity of typically and preferably at least 18 MS2 = cm
at 25 C. This
ensures residual inorganic impurities such as salts are less than 1 ppb.
The purity of the oligonucleotides, in particular, of the oligonucleotide G10
of SEQ ID
NO:1, was determined by ion-pair, reversed-phase high performance liquid
chromatography
(IP-RP-HPLC) or by anion exchange ¨ high performance liquid chromatography
(IEX-
HPLC).
CA 03096311 2020-10-06
WO 2019/197965
PCT/IB2019/052867
IP-RP-HPLC was effected using a Waters Xbridge BEH C18 4.6 x 75 mm,
column at a column temperature of 70 2 C, a flow rate of 0.4 mL/min, a
wavelength of
260nm, an injection volume of 5 L and a run time of 40 minutes.
IEX-HPLC was effected using a Dionex DNAPac PA200 4.0 x 250 mm part # 063000
5 column at a column temperature of 30 2 C, a flow rate of 1.0 mL/min, a
wavelength of
260nm, an injection volume of 20 L and a run time of 45 minutes.
IP-RP-HPL.0 // G10: Samples are injected on a oligonucleotide ion pairing
column and
elution is carried out using a combined water acetonitrile gradient modified
with TEA and
HFIP as the ion pairing buffer with detection at 260 nm. The resulting
oligonucleotide G10
10 peak is integrated separately from the remaining peaks consisting of
oligonucleotide G10
subpopulations such as G10+1n, G10-1n, G10-2n, G10-3n, >G10+1n and <G10-3n
(whereby
n = deoxynucleotide).
IEX-HPLC // G10: Samples are injected on a strong anion-exchange column and
analyzed under denaturing conditions (pH >10). Elution is carried out using a
combined salt
15 and methanol gradient with detection at 260 nm. The resulting
oligonucleotide G10 peak is
integrated separately from the remaining peaks consisting of oligonucleotide
G10
subpopulations such as G10+1n, G10-1n, G10-2n, G10-3n, >G10+1n and <G10-3n
(whereby
n = deoxynucleotide).
EXAMPLE 1
20 Denaturation and Aggregation of Oligonucleotide G10 (SEQ ID NO:1)
Quantification of G10: Oligonucleotide G10 (SEQ ID NO:1) was quantified by UV
absorption at 260 nm corrected by the absorption at 340 nm, wherein 1 A260-340
corresponds
to a concentration of 27.8 tg / ml at 1 cm path length.
Denaturation: (10.0 ml scale, 500 i.tM G10 of a purity of about 94% as
determined by
25 reverse phase HPLC and anion Exchange HPLC (referred to as high purity G10
oligonucleotide in this Example section), 1M Urea, 85 C, 20 min): 70.6 mg G10
were
weighed into a 15 ml tube. The powder was dissolved in 10.0 ml purified water
(with a
resistivity at 25 C of 18.2 MS/ = cm) containing 1M urea (c= 500pM; content of
bulk powder
determined prior to dilution by spectrometry). The mixture was disaggregated
for 20
30 minutes at 85 C in a water bath. Aliquots were taken, immediately cooled
down in an
ice/water bath to 0 C, removed from the ice bath, and allowed to warm to room
CA 03096311 2020-10-06
WO 2019/197965
PCT/IB2019/052867
36
temperature naturally, and DLS and optionally size exclusion HPLC (SEC)
measurements
conducted as described in Example 3 and Example 4. The remainder of the sample
was
held at 85 C and the aggregation step conducted.
Fig. 1A shows a DLS of the denatured high purity G10 oligonucleotide obtained
with
the inventive process as a single peak. The measured average diameter of the
G10
oligonucleotide of 0.90 nm indicates that denaturing is complete and monomers
have been
achieved. This fully denatured G10 oligonucleotide ensures and allows the
formation a
well-controlled and defined aggregated G10 oligonucleotides within the desired
range in
accordance with the present invention as outlined below.
Aggregation (20.0 ml scale, 250 i.tM G10 denatured as above, 250 mM NaCl- 20
mM Sodium Phosphate (pH=7.2), 1M urea 85 C, 8-30 min): 10 ml of the denatured
500
i.tM G10 solution at 85 C referred above were mixed with a solution of 10 ml
of 500mM
NaCl, 40 mM Sodium Phosphate, and 1M urea at 85 C in a 25 ml tube. The mixture
was
incubated for 15 minutes at 85 C in a water bath. The solution was cooled down
in an
ice/water bath to 0 C. Aliquots were taken therefrom, allowed to warm to room
temperature, and DLS and optionally size exclusion HPLC (SEC) measurements
conducted. Aggregated oligonucleotide solutions are typically and preferably
used within 3
hours if stored <20 C.
A final filtration step can be utilized to remove eventual trace (<1%) of
large
particles. This is performed by passing the previously cooled, room
temperature solution of
aggregated oligonucleotides through a 50 nm filter.
Fig. 1B shows a DLS of the subsequently aggregated G10 oligonucleotides
obtained
with the inventive process. The very preferred aggregated G10 oligonucleotides
obtained
show proper aggregation and an average diameter of 12 nm. These well-
controlled and
defined aggregated G10 oligonucleotides within the desired preferred range in
accordance
with the present invention will result in very high purity packaged and well-
formed VLPs
as outlined below.
The denaturation and aggregation of the very preferred oligonucleotide G10
(SEQ ID
NO:1) were further conducted at different oligonucleotide concentrations,
wherein basically
.. the same DLS as depicted in FIG. lA and FIG. 1B were obtained. Thus,
denaturation was
effected using various concentrations of the oligonucleotide G10 of between
100 m and
1mM. The subsequent aggregation step were then effected by exactly half that
concentration as used for the denaturation as a matter of convenience due to a
1:1 mixing of
CA 03096311 2020-10-06
WO 2019/197965
PCT/IB2019/052867
37
the two solutions as described herein.
EXAMPLE 2
Denaturation and Aggregation of Oligonucleotides G10-11, G12-11, G6, G7, G8,
G9,
G11, G6-10, G7-10, G8-10, and G9-10 (SEQ ID NOs: 3-9, 24-27)
Denaturation: A solution of 500 i.tM oligonucleotide G10-11 (SEQ ID NO:3), G12-
11
(SEQ ID NO:4), G6 (SEQ ID NO:5), G7 (SEQ ID NO:6), G8 (SEQ ID NO:7), G9 (SEQ
ID
NO:8), Gil (SEQ ID NO:9), G6-10 (SEQ ID NO:24), G7-10 (SEQ ID NO:25), G8-10
(SEQ
ID NO:26) or G9-10 (SEQ ID NO:27) in 1M urea was disaggregated for 20 minutes
at 85 C
in a water bath.
Aggregation: (10.0 ml scale, 250 i.tM G10, 250 mM Nat, 20 mM Sodium Phosphate,
1M urea 85 C, 8-30 min): 5 ml denatured solution of oligonucleotides G10-11
(SEQ ID
NO:3), G12-11 (SEQ ID NO:4), G6 (SEQ ID NO:5), G7 (SEQ ID NO:6), G8 (SEQ ID
NO:7), G9 (SEQ ID NO:8), Gil (SEQ ID NO:9), G6-10 (SEQ ID NO:24), G7-10 (SEQ
ID
NO:25), G8-10 (SEQ ID NO:26) or G9-10 (SEQ ID NO:27) at 85 C, 5 ml of 500mM
Nat, 40
mM Sodium Phosphate, and 1M urea at 85 C were mixed in a 15 ml tube (250 i.tM
oligo, 1 M
urea, 20 mM Sodium Phosphate, 250 mM Nat). The mixture was incubated for 15
minutes at
85 C in a water bath. The solution was cooled down in an ice/water bath to 0
C. Aliquots
were taken therefrom, allowed to warm to room temperature, and DLS and
optionally size
exclusion HPLC (SEC) measurements conducted. Aggregated oligonucleotide
solutions are
typically and preferably used within 3 hours if stored <20 C.
The products of the aggregation processes were analyzed by Dynamic Light
Scattering (DLS) as described in Example 3 and by size exclusion HPLC as
described in
Example 4. DLS of the aggregated oligonucleotides revealed that the average
diameter of
all the aggregated oligonucleotides were between 11-13 nm, as determined by
Dynamic
Light Scattering (DLS), and all within 80%-110% PST, as determined by size
exclusion
HPLC.
EXAMPLE 3
Analysis of the Aggregation of oligonucleotide G10 by Dynamic Light Scattering
The particle size of the oligonucleotides, aggregated oligonucleotides and
VLPs
packaged with aggregated oligonucleotides in accordance with the present
invention was
CA 03096311 2020-10-06
WO 2019/197965
PCT/IB2019/052867
38
determined using dynamic light scattering (DLS). Instrument settings as used
for the present
examples and as preferred for determining the particle size of the
oligonucleotides,
aggregated oligonucleotides and VLPs packaged with aggregated oligonucleotides
in
accordance with the present invention are presented below.
Instrument: Malvern Zetasizer Nano ZS
Light Source: He-Ne laser (633nm at 4mW (maximum))
The middle column of Table 1 represents the settings applied for a reference
standard
(polystyrene microspheres) and for calibration that confirmed that the
instrument was
performing properly. The right column represents the settings applied in the
method used for
our analysis and measurements of the oligonucleotides, aggregated
oligonucleotides and
VLPs packaged with aggregated oligonucleotides.
Table 1: Instrument settings for standard and inventive compositions
mirosphre packaged VLPs
Type: Size Size
Material: Polystyrene Latex DNA/Protein
Refractive Index RI: 1.59 1.45
Absorbance (ABS): 0.01 0
Dispersant: H20 PBS
Temperature: 25 C 25 C
Viscosity: 0.8872 cP 1.33 cP
Refractive Index RI: 1.33 1.33
Equilibration time: 20 sec 60 sec
Detection angle: 1730 (backscatter) 173 (backscatter)
Run duration: 10 sec 30 sec
Number of runs per 3-5, preferably 3 3-5, preferably 3
measurement:
The DLS software calculates average hydrodynamic radii, and through basic
multiplication, the particle average diameter is determined. 2 x particle
average radius =
Particle diameter. For consistency, particle size will henceforth be reported
and used
throughout the present invention as average diameter measured in nanometers
(DHyd).
EXAMPLE 4
Analysis of the Aggregation of oligonucleotide G10 by Size Exclusion HPLC
CA 03096311 2020-10-06
WO 2019/197965
PCT/IB2019/052867
39
The aggregation state of the aggregated G10 oligonucleotides was analyzed
essentially as described in WO 2007/144150 by analytical size exclusion HPLC
using the
following conditions:
Column: TSKgel 5000 PWXL 7.8 mm * 30.0 cm
(Lot: 5PWX06GNMH3304, Art: 08023, Tosoh Bioscience)
Eluent: PBS (150 mM NaCl in 20 mM sodium phosphate
buffer,
pH 7.2)
Injection volume: 40.0 ill (preferably comprising a concentration
of about 20
i.tM to about 500 i.tM)
Flow rate: 0.8 ml/min
Gradient: Isocratic
Run time: 20 min
Wavelength: 215, 260 and 280 nm, data evaluation at 260 nm
Column oven temp.: 25 C
Auto s ampler temp.: 8 C
Capsid of bacteriophage QI3 was used as standard.
The peak start time X % of G10 relative to QI3 capsid (relative peak start
time QI3) was
calculated as follows: X % = peak start time [min] of the oligonucleotide
divided by the
retention time of QI3 capsid standard [min] x 100 %, wherein the peak start
time of the
oligonucleotide was determined as the time when the elution of the
oligonucleotide became
detectable, and wherein the retention time of the QI3 capsid standard was
determined as the
time of the occurrence of the maximum peak of the standard. An Example of an
elution
profile of oligonucleotide G10 and capsid of bacteriophage QI3 as standard is
depicted in
Figure 1 of W02007/144150. Based on the chromatograms depicted in Figure 1 of
W02007/144150 a relative peak start time of 88 % was calculated for the
aggregated
oligonucleotide.
EXAMPLE 5
Comparison of denatured oligonucleotides G10 obtained by the inventive process
and by
prior art processes
The oligonucleotide G10 of SEQ ID NO:1 with two different purities (79% and
94% as
determined by reverse phase HPLC and anion Exchange HPLC; referred to as low
and high
CA 03096311 2020-10-06
WO 2019/197965
PCT/IB2019/052867
purity G10 oligonucleotide in this Example section) were each subjected to the
disaggregation
(denaturation) as described in the prior art (W02007/144150). The same high
purity (94%)
oligonucleotide G10 was subjected to the denaturation as described in Example
1 herein. The
impurities of the used oligonucleotide G10 are mostly "failure sequences"
meaning
5 oligonucleotide sequences with lower number of G residues, be it 26 mers,
27 mers, 28 mers
and 29 mers.
The resulting products were analyzed by DLS as described in Example 3 and are
shown
in FIG. 2A (Low purity G10, prior art process) and FIG. 2B (High purity G10,
prior art
process) and Fig. 2C (High purity G10, inventive process). The completely
denatured
10 oligonucleotide G10 monomer has a hydrodynamic average diameter of
approximately 1 nm.
The low purity G10 subjected to the denaturing prior art process resulted in
particles
with an average diameter of 2.2 nm indicating the presence of secondary
structures and that
not all oligonucleotide G10 has been completely denatured to monomer (FIG.
2A). The high
purity G10 subjected to the denaturing prior art process resulted in particles
with an average
15 diameter of 2.8 nm indicating the presence of secondary structures and
that not all
oligonucleotide G10 has been completely denatured to monomer (FIG. 2B). As
will be
discussed in Example 6, this incomplete denaturing will lead to more variable,
and further to
larger, aggregated oligonucleotides.
The high purity G10 subjected to the denaturing of the inventive process
resulted in
20 particles with an average diameter of 0.9 nm indicating that
oligonucleotide G10 has been
completely or substantially completely denatured to monomer (FIG. 2C). As
indicated, this
fully denatured G10 oligonucleotide ensures and allows the formation of well-
controlled
and defined aggregated G10 oligonucleotides within the desired range in
accordance with
the present invention.
25 The proper denaturing of the oligonucleotides such as shown for the very
preferred
oligonucleotide G10 leading to complete, or at least almost complete,
denaturing and to
monomers prior to the start of the aggregation step is highly preferred and
important. If
secondary structures exist, dimers, trimers, or quadruplexes of the
oligonucleotides, the
aggregation step will be more variable, and the final aggregated
oligonucleotides will be
30 larger and of a broader size distribution.
CA 03096311 2020-10-06
WO 2019/197965
PCT/IB2019/052867
41
EXAMPLE 6
Comparison of aggregated oligonucleotides G10 obtained by the inventive
process and
by prior art processes
The G10 materials obtained from the denaturing experiments as described in
Example 5
were subjected to aggregation, either as described in the prior art
(W02007/144150), or as
described by the inventive process, and hereby as described in Example 1
above.
The resulting aggregated oligonucleotides were analyzed by DLS as described in
Example 3 herein and are shown in FIG. 3A (prior art aggregation of low purity
G10
denatured by prior art process) and FIG. 3B (prior art aggregation of high
purity G10
denatured by prior art process) and Fig. 3C (inventive aggregation of high
purity G10
denatured by inventive process).
The low purity material denatured and aggregated with the prior art process
resulted in
aggregated oligonucleotides which are not only on the high side of the desired
average
diameter range (6-16 nm), but additionally, 10% of the material is too large
(30-40 nm) for
subsequent proper packaging into VLP' s of RNA bacteriophages, preferably of
RNA
bacteriophages QI3 (FIG. 3A). As a result of this larger and wide particle
distribution, the final
packaged VLPs will be less pure by SEC and DLS and rod like structures will be
observed in
the electron micrographs (see Example 8 below). It has to be noted that said
rod like
structures cannot typically be separated by purification via filtration but
requires more costly
and intense purification via chromatography which is very detrimental for
manufacturing at
scale, and in particular, for GMP manufacturing.
The high purity material denatured and aggregated with the prior art process
resulted in
aggregated oligonucleotides all of which are too large for packaging into VLP'
s of RNA
bacteriophages, preferably of RNA bacteriophages QI3, and, therefore will
result in unstable
VLPs (FIG. 3B). Additionally, a second peak at - 100 nm is identified. It is
noteworthy that
optimization of the prior art process using the high purity material by
decreasing the time of
aggregation was not performed due to the fact that the then required heating
and cooling times
would be shorter than what could be easily controlled at either the lab or at
manufacturing
scale. The present inventive processes were, in fact, able to overcome said
disadvantage of the
prior art processes.
Thus, and to the contrary, the high purity material denatured and aggregated
with the
process of the present invention resulted in aggregated oligonucleotides
having an average
diameter of 12 nm indicating proper aggregation (FIG. 3B). This well-
controlled and defined
CA 03096311 2020-10-06
WO 2019/197965
PCT/IB2019/052867
42
aggregated G10 oligonucleotides within the desired very preferred range in
accordance with
the present invention will result in very high purity and well-formed packaged
VLPs.
The proper aggregation of the oligonucleotides such as shown for the very
preferred
oligonucleotide G10 leading to a complete, or at least almost complete,
narrowly defined
diameter size distribution is further highly preferred and important.
Controlling the
aggregation leading to aggregated oligonucleotides of an average diameter of
11-13 nm,
preferably of an average diameter of 12 nm, as determined by DLS as described
in
Example 3 ensures and allows to achieve a high purity packaged VLP.
If the aggregated oligonucleotides are too big, the resulting material after
the packaging
step will have large impurities as shown in the DLS, and malformed VLPs such
as rod like
structures as shown in the electron micrographs. If the aggregated
oligonucleotides are very
large >50 nm, unstable VLPs can result.
EXAMPLE 7
Packaging of QI3 VLPs with Aggregated Oligonucleotides G10 by Disassembly /
Reassembly
Disassembly of QI3 VLPs: 45 mg QI3 VLP (2.5 mg/ml, as determined by Bradford
analysis) in PBS (20 mM Phosphate, 150 mM NaCl, pH 7.5), was reduced with 10
mM
DTT for 15 min at RT under stirring conditions. Then, magnesium chloride was
added to
0.7 M final concentration and the incubation was continued for 15 min at RT
under stirring
conditions, leading to precipitation of the encapsulated host cell RNA and
concomitant
disintegration of the VLPs. The solution was centrifuged 10 min at 4000 rpm at
4 C
(Eppendorf 5810 R, in fixed angle rotor A-4-62 used in all following steps) in
order to
remove the precipitated RNA from the solution. The supernatant, containing the
released,
dimeric QI3 coat protein, was used for the chromatographic purification steps.
In an alternative and preferred manner, the Qbeta capsid was disassembled into
Qbeta
dimer by the addition of 1 M DTT to a final concentration of 10 mM DTT.
Nucleic acid
and host cell proteins were precipitated by increasing the NaCl concentration
to 600 mM
and adjusting the pH to pH 2.6 by the addition of 1 M Sodium Phosphate, 0.75 M
Citric
Acid. The precipitated nucleic acids and HCP were removed by TFF using a
Sartoflow
Beta Crossflow system fitted with 2 x 0.5 m2 Millipore Biomax 300 membranes
ran using
the following operating parameters: P
- Feed = 0.9, PRetentate = 0.4 bar and P
- Permeate = 0.2 bar
CA 03096311 2020-10-06
WO 2019/197965
PCT/IB2019/052867
43
resulting in a TMP of 0.45 bar. The material was diafiltered against 3 DVs of
20 mM
Sodium Phosphate, 20 mM Citric acid, 300 mM Sodium Chloride pH 3.3.
Purification of 013 coat protein by cation exchange chromatography and size
exclusion chromatography: The supernatant of the disassembly reaction,
containing dimeric
coat protein, host cell proteins and residual host cell RNA, was loaded onto a
SP-Sepharose
FF column (xkl6/20, 6 ml, Amersham Bioscience). The column was equilibrated
with 20
mM sodium phosphate buffer pH 7 and the sample was diluted 1:15 in water to
adjust a
conductivity below 10 mS/cm in order to achieve proper binding of the coat
protein to the
column. The elution of the bound coat protein was accomplished by a step
gradient to 20
mM sodium phosphate / 500 mM sodium chloride and the protein was collected in
a
fraction volume of approx. 25 nil. The chromatography was carried out at RT
with a flow
rate of 5 ml/min during all steps and the absorbance was monitored at 260 nm
and 280 nm.
In a second step, the isolated Qf3 coat protein (the eluted fraction from the
cation exchange
column) was loaded onto a Sephacryl S-100 HR column (xk26/60, 320 ml, Amersham
Bioscience) equilibrated with 20 mM sodium phosphate / 250 mM sodium chloride;
pH
7.2. The chromatography was carried out at RT with a flow rate of 2.5 ml/min
and the
absorbance was monitored at 260 nm and 280 nm. Fractions of 5 ml were
collected.
Characterization of purified OP coat protein by analytical size exclusion
chromatography: A sample of purified Qf3 coat protein was analyzed by
analytical size
exclusion chromatography (FIG. 4C) and compared to i) intact Qf3 VLP (FIG.
4A), which
had been purified from E.coli lysate and which was used as source material for
the
purification procedure, and ii) to the supernatant of the disassembly reaction
(FIG. 4B).
Efficient separation of RNA molecules from the coat protein is indicated by
the absence of
any RNA-like peak (typical ratio of A280/A260 = 0.5) in FIG. 4C and the
presence of a
unique protein-like peak (typical ratio of A280/A260 = 1.7).
In an alternative and preferred manner, purification of 013 coat protein were
effected
by cation exchange chromatography and Mustang Q membrane: CEX Chromatography
was
performed as a capture step for the Qbeta dimer. SP Sepharose FF resin was
packed into a
BPG140 column using an AKTA Ready Chromatography system and 150 mM NaCl as the
packing buffer. The bed height of the packed column was 14.0 cm, equivalent to
a bed
volume of 2.2 L. HETP analysis gave an asymmetry factor of 1.55 and a
theoretical plate
count of 2560 plates per meter. The diafiltrate from the disassembly step was
filtered
through a Millipore Opticap XL 5 capsule prior to loading. Chromatography was
CA 03096311 2020-10-06
WO 2019/197965 PCT/IB2019/052867
44
performed using the method shown in Table 2.
Table 2: Cation Exchange Chromatography Method
Step Buffer CV
Sanitisation 0.5 M NaOH (5 hr contact time) 5
Equilibration 20 mM Sodium Phosphate
300 mM NaC1 pH 3.3 5
Load CEX Load
Up to 15 g/L
Wash 1 20 mM Sodium Phosphate, 300 mM NaC1 pH 3.3 5
Wash 2 20 mM Sodium Phosphate, 300 mM NaC1 pH 7.2 10
Elution 20 mM Sodium Phosphate, 550 mM NaC1 pH 7.2 5
High Salt Regeneration 20 mM Sodium Phosphate, 1150 mM NaC1 pH 7.2 3
CIP 0.5 M NaOH (5 hr contact time) 3
Storage 20% (v/v) Ethanol, 0.1 M NaC1 1.5
A flow rate 144 cm/h for Sanitisation and Equilibration. 216 cm/h was used for
all other steps.
Filtration through a Mustang Q capsule was performed to reduce endotoxin and
any
residual nucleic acid. The CEX Pool was initially filtered using a 0.2 tm
Millipak 60 filter
(Cat. No. MPGLO6GH2) prior to filtration through a Mustang Q filter at a flow
rate of 200
ml/min. The flowthrough collected from the Mustang Q filter was then passed
through a
second 0.2 tm Millipak 60 filter.
Assembly of Qr3G10 by diafiltration: Purified coat protein (in 20 mM sodium
phosphate pH 7.2, 250 mM NaCl) was mixed with water and stock solutions of
urea, NaCl,
DTT and aggregated G10 oligonucleotides (prepared as described in Example 1).
The
volume of the mixture was 50 ml and the final concentrations of the components
were 1
mg/ml coat protein, 1.0 M urea, 250 mM NaCl, 2.5 mM DTT and 0.24 mg/ml G10.
The
solution was then diafiltrated at room temperature against 300 ml of 20 mM
sodium
phosphate 250 mM NaCl pH 7.2, using a 30 kDa cut off cartridge (Pellicon XL,
Millipore)
and a cross flow rate of 10 ml/min and a permeate flow rate of 2.5 ml/min.
H202 was added
to 7 mM final concentration and the solution incubated for lh at RT in order
to induce the
formation of disulfide bonds. The solution was then diafiltrated against 500
ml of 20
CA 03096311 2020-10-06
WO 2019/197965
PCT/IB2019/052867
mM sodium phosphate 150 mM NaC1 pH 7.2, using a 300 kDa cut off cartridge
(Pellicon
XL, Millipore) and a cross flow rate of 10 ml/min and a permeate flow rate of
2.5 ml/min,
in order to remove excess of H202 and non-packaged G10 oligonucleotides from
the
assembled %Gil) product.
5 Alternatively, the packaging of QI3 VLPs with the aggregated
oligonucleotides G10
as obtained by the present invention can also further be effected as described
in Example 10
of W02007/144150.
EXAMPLE 8
Comparison of Q13 VLPs packaged with aggregated oligonucleotides G10 as
obtained by
10 the present invention and by prior art processes ¨ DLS and EM
QI3 VLPs were prepared in analogy to Example 7 described above using not only
the
aggregated G10 oligonucleotides prepared as described in Example 1, but
further using the
aggregated G10 oligonucleotides prepared by the prior art processes as
described in Example
6 above.
15
The aggregated oligonucleotides shown in FIG. 3A, which were obtained by prior
art
aggregation of low purity G10 denatured by prior art process, and having a
wide size
distribution with 10% being too large for packaging, when subjected to the
packaging step
resulted in VLPs having a DLS as shown in FIG. 5A and an EM as shown in FIG.
5B. The
DLS revealed a major peak (96%) of an average diameter of 28 nm corresponding
to properly
20
formed VLPs (30 nm 2 nm), but additional large particle peaks were observed
as well. The
corresponding EM shows spherical VLPs with said average diameter, but also rod
like
structures much larger than the desired 30 nm VLPs.
To the contrary, the high purity material denatured and aggregated with the
process of
the present invention when subjected to the packaging step resulted in
packaged VLP's of one
25
average diameter and purely formed VLPs. The DLS shows one single peak at 30
nm and no
large particles (FIG. 5C) and the EM shows all spherical VLPs with no rod like
structures
(FIG. 5D).
EXAMPLE 9
Denaturing Step of the Inventive Process effected with varied parameters
CA 03096311 2020-10-06
WO 2019/197965
PCT/IB2019/052867
46
The denaturation of oligonucleotide G10 (SEQ ID NO:1) as described in Example
1
was investigated by varying the concentration of urea, denaturing time, and
temperature
applied for said denaturation. A bulk oligonucleotide G10 solution was
obtained by dissolving
G10 (high purity of 94%) in water to a concentration of 1 mM. Urea solutions
were added to
obtain final denaturing solutions of 500 1..tM G10 with urea concentrations
from 0.1M to 1M.
Aliquots of these samples were then incubated at a range of temperature
between 25 C and
85 C for 20 or 60 minutes. Samples were immediately cooled down in an
ice/water bath to
0 C, removed from the ice bath, and allowed to warm to room temperature
naturally, and
DLS measurements as described in Example 3 conducted. Table 3 shows that
successful
denaturing, i.e. an average diameter of mm or less, can be achieved
irrespective of the urea
concentration of 0.2 M to 1.0 M.
Table 3: Urea Concentration and Temperature Impact on G10 Oligonucleotide
Denaturing
O. 1M 60 85 No
0.2M 60 85 Yes
0.5 M 20 85 Yes
1.0 M 60 75 Yes
1.0 M 20 85 Yes
1.0 M 60 85 Yes
